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ABSTRACT

THE EFFECTS OF SELENIUM ON ESTROGEN-REGULATED GENE EXPRESSION
IN LNCAP PROSTATE CANCER CELLS

Tory L. Parker
Department of Nutrition, Dietetics and Food Science
Master of Science

Prostate cancer is the most frequently diagnosed cancer in American men and the
second leading cause of cancer deaths. Supplementation with Se has reduced the
incidence of prostate cancer and Se status is inversely correlated with prostate cancer
risk. One molecular mechanism by which high Se concentrations may affect cancer risk
is by catalyzing disulfide bond formation or otherwise complexing with reactive
sulfhydryl groups in cellular proteins. The estrogen receptor (ER) contains cysteines in
zinc (Zn) fingers that are susceptible to oxidation and internal disulfide formation, which
can prevent DNA binding. We examined ER binding to its DNA response element and
gene expression levels for estrogen-regulated genes in human prostate cancer cells
(LNCaP) treated with control (50 nM) or high (5 µM) concentrations of Se. High Se
treatment resulted in a non-significant 16 % decrease in ER binding to the estrogen
response element (ERE), and no significant changes were found in expression levels of

estrogen-regulated genes for either run-on nuclear transcripts or total mRNA. The well
documented reaction of Se with reactive sulfhydryl groups, if it occurs in the ER in vivo,
has a minimal effect on the binding of ER to DNA and its regulation of gene expression.
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ABSTRACT
Prostate cancer is the most frequently diagnosed cancer in American men and the
second leading cause of cancer deaths. Supplementation with Se has reduced the
incidence of prostate cancer and Se status is inversely correlated with prostate cancer
risk. One molecular mechanism by which high Se concentrations may affect cancer risk
is by catalyzing disulfide bond formation or otherwise complexing with reactive
sulfhydryl groups in cellular proteins. The estrogen receptor (ER) contains cysteines in
zinc (Zn) fingers that are susceptible to oxidation and internal disulfide formation, which
can prevent DNA binding. We examined ER binding to its DNA response element and
gene expression levels for estrogen-regulated genes in human prostate cancer cells
(LNCaP) treated with control (50 nM) or high (5 µM) concentrations of Se. High Se
treatment resulted in a non-significant 16 % decrease in ER binding to the estrogen
response element (ERE), and no significant changes were found in expression levels of
estrogen-regulated genes for either run-on nuclear transcripts or total mRNA. The well
documented reaction of Se with reactive sulfhydryl groups, if it occurs in the ER in vivo,
has a minimal effect on the binding of ER to DNA and its regulation of gene expression.
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INTRODUCTION
Prostate cancer is the most frequently diagnosed cancer in American men and the
second leading cause of cancer deaths. The American Cancer Society estimates that
prostate cancer will account for 33% of new cancers in men, totaling over 230,000 new
cases, with 29,900 deaths in 2004 (39). Supplementation with 200 µg of Se in the trials of
Clark et al. reduced the incidence of prostate cancer (4). The most recent analysis of their
data showed the greatest benefit from Se supplementation in men in the lowest two
tertiles of baseline serum Se (7). High Se status has been correlated with reduced prostate
cancer risk (44, 45, 48) and may slow the progression of prostate cancer tumors (29).
Dietary supplementation with Se compounds may represent a viable option to reduce
incidence, morbidity, and mortality of prostate cancer (31).
The mechanisms for Se's protective effects have not been fully explored, though
many possible molecular targets have been identified (13, 23, 38, 47). Ganther (8, 9)
proposed that one molecular mechanism by which high Se concentrations may affect
cancer risk is by catalyzing disulfide bond formation or otherwise complexing with
reactive sulfhydryl groups in cellular proteins. Formation of such structures has been
demonstrated in catalytic proteins (11). Our laboratory has recently provided evidence
consistent with a Se-S interaction in the redox-regulated transcription factor NF-κB (41).
Another transcription factor whose activation may be regulated by disulfide bond
formation is the estrogen receptor (ER). ER binding to DNA is strongly influenced by the
redox state of the cell (46), as the ER contains cysteines in zinc (Zn) fingers that are
susceptible to oxidation and internal disulfide formation, which can prevent DNA binding
(1). Dimerization of the ER is required for activity, with one Cys4-type zinc finger found
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in the DNA-binding domain and one in the dimerization domain (46). Whittal et al. (46)
showed that ER redox sensitivity is likely related to the Zn finger in the dimerization
domain and that Zn is expelled from the Zn finger previous to disulfide formation when
treated with H2O2 or diamide. Jacob et al. (17) detailed the conditions under which Se
compounds can catalyze the release of Zn from Zn fingers, even under reducing
conditions, as found in vivo.
The effects of estrogen are mediated through the ER. The roles of estrogen in
prostate cancer have recently been reviewed (15, 37) and animal models and human
epidemiological studies have implicated estrogen as a promoter of prostate cancer in its
early stages (40). If Se compounds displace Zn in the ER Zn fingers and catalyze
disulfide bond formation, then ER binding to DNA and expression of ER-regulated genes
should decrease. To test this hypothesis, we examined ER binding to its DNA response
element and gene expression levels for estrogen-regulated genes in human prostate
cancer cells (LNCaP) treated with control (50 nM) or high (5 µM) concentrations of Se.
MATERIALS AND METHODS
Cell Culture
LNCaP human prostate cancer cells (cell line established from a 50-year old male
lymph node metastasis, ATCC, Manassas, VA) were maintained in RPMI 1640 with
phenol red (ATCC, Manassas, VA) modified by ATCC to contain: 2 mM L-glutamine,
10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and 150 mg/L sodium
bicarbonate. Media was further supplemented to contain 10% Fetal Bovine Serum (FBS,
HyClone, Logan, UT), 1% penicillin-streptomycin solution (Sigma-Aldrich Corp., St.
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Louis, MO), and 30 µM (±)-α-tocopherol (Sigma-Aldrich Corp., St. Louis, MO). Cells
were incubated at 37°C in 5% CO2.
Conventional cell culture media typically provide concentrations of antioxidants
far lower than those found in human plasma. Liest et al. (27) showed that this may
increase the risk of peroxide-induced genotoxicity. In their trials, supplementation with
50 nM Se and 30 µM α-tocopherol eliminated single strand DNA breaks induced by
H2O2 and maximized the activity of Se-dependant glutathione peroxidase in all cell lines
examined. In our experiments, all media were supplemented to provide these
concentrations of antioxidants.
To examine the effects of Se treatment, 90% confluent 25 cm2 flasks of LNCaP
cells were passaged 1:2 to new 25 cm2 flasks and equilibrated for 48 hours in phenol redfree RPMI 1640 medium (Sigma-Aldrich Corp., St. Louis, MO) modified to be identical
to maintenance medium above, except that estrogen content was supplemented to 30
pg/mL to be within the range of normal male serum levels (22). Prostate cancer patients
do not have significantly increased or decreased levels of estrogen compared to healthy
men (32, 42). Phenol red-free medium was used to eliminate any possible estrogenic
effects of phenol red (2). After 48 hours, medium was completely removed and fresh
phenol red-free estrogen-supplemented medium was added. Half of the flasks received
medium containing 50 nM Se and half received medium providing 5 µM Se as
methylseleninic acid (CH3SeO2H, MSA). Cells were then incubated 72 hours and
harvested.
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Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared from harvested cells using a Panomics Nuclear
Extraction Kit (Panomics, Inc., Redwood City, CA), with the following modifications: As
cells were cultured in flasks, rather than dishes, cells were trypsinized with 0.025%
Trypsin/0.265 mM EDTA solution (Cambrex Bio Science Walkersville, Inc.,
Walkersville, MD), removed from the flasks and washed twice with phosphate buffered
saline (PBS) (after 10 minute spins at 125 x g following each wash). Before proceeding
with the isolation as outlined in the Panomics kit instructions, cells were then transferred
to 1.5 mL Eppendorf tubes in Buffer A mix and the remainder of the protocol was
followed as outlined, including dialysis with Buffer C and Slide-A-Lyzer Dialysis
cassettes (Pierce, Rockford, IL). Protein was quantified using Bradford reagent (SigmaAldrich Corp., St. Louis, MO).
Table 1 lists the forward and reverse sequences of the 46-mer estrogen response
element (ERE) from the Xenopus vitellogenin A2 gene used in previous studies of ER
interaction (36), which was chosen for use in these experiments. Single strands (BioSynthesis Incorporated, Lewisville, TX) were mixed to a 5 µM concentration each,
heated to 75°C for 15 min, then allowed to cool slowly at room temperature (RT) for 30
minutes and stored at -20°C. Aliquots were end-labeled with P32 using T4 polynucleotide
kinase (Fisher BioReagents, Fairlawn, NJ). Incubation followed the formula of García
Pedrero et al. (10) as follows: 10 µL buffer B (20 mM HEPES-KOH, pH 7.9; 10 mM
MgCl2; 1 mM EDTA; 10 % (vol/vol) glycerol; 100 mM KCl; 0.2 mM
phenylmethylsulfonyl fluoride (PMSF); 0.2 mM dithiothreitol; 0.5% Nonidet P-40; and
protease inhibitors), 1 µL Poly (dIdC)*Poly(dIdC) (prepared to 1 µg/µL, Amersham
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Biosciences, Piscataway, NJ), 1 µL 150x cold competitor, when appropriate (5 µM ERE
diluted 1:2), 5 µg nuclear protein, and water to equal 20 µL, then incubated 15 minutes at
4°C. Next, 1 µL radiolabeled probe was then added, reaction mixtures were incubated 1
hour at 4°C and 30 minutes at RT, and loaded into the lanes of a 5% polyacrylamide gel
(polyacrylamide:bisacrylamide, 39:1) in 0.5x TBE. The gel was pre-run (before addition
of reaction mixtures) at 150 V until mA reached ~18 (1-1.5 hrs). Samples were then
loaded and run at 100 V for 2-3 hrs (until dye front (bromophenol blue/xylenol orange)
was 2-3 cm from the bottom). Gels were dried under vacuum at 80°C for 60 min,
exposed to Kodak BioMax MS film (Eastman Kodak Company, Rochester, NY) at -80°C
for 1-18 hrs (depending on the age of the probe), and developed. Densitometric analysis
(Spot Densitometry, AlphaEase software, Alpha Innotech, San Leandro, CA) was
performed on multiple exposures of three separate EMSA gels.
Gene Selection
The genes chosen for study in the run-on transcription assay and steady-state
mRNA experiments are regulated by estrogen in the prostate, and are expressed in the
LNCaP cell line. IGFBP10 (14) is important for growth and proliferation, and is one of a
family of insulin-like growth factor binding proteins. In previous work high Se intake
induced a significant reduction in IGF-1 levels in circulation in rats (12), suggesting Se
could affect IGFBP10 levels. Cdk2 (21, 28), a regulator of the cell cycle, is involved in
prostate tumor progression and is associated with uncontrolled tumor cell proliferation. It
is more highly expressed in LNCaP cells than the prostate cancer cell lines PC3 or
DU145. Cathepsin D (24, 25) is a lysosomal protease. It plays a role in cell proliferation
and development in prostate cancer, and is also highly expressed in LNCaP cells. HpS2
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(18, 26), also known as trefoil factor 1 (TFF1), serves as a marker of malignancy in
various cancer types, including prostate (5). It is expressed in LNCaP cells, and is
induced by estrogen.
Run-on Transcription Assay
To determine the effects of Se on transcription rates for each gene of interest,
nuclei were isolated according to instructions in the Panomics Nuclear Extraction Kit,
stopping after gentle lysing of the cellular membrane but maintaining nuclei intact. Runon transcription was carried out according to the method of Patrone et al. (34) using
biotinylated UTP (Roche Diagnostics Corp., Indianapolis, IN) to label nascent transcripts
and streptavidin-coated magnetic beads (Dynal Biotech LLC, Brown Deer, WI) to isolate
them. Reverse transcription was performed using Superscript II RNase H- Reverse
Transcriptase (Invitrogen Life Technologies Corp., Carlsbad, CA) and first strand cDNA
was purified using the QIAquick PCR Purification Kit (QIAGEN Sciences, Inc.,
Germantown, MD). Nascent transcripts for the genes of interest were quantified using
real-time RT-PCR.
Primers were designed for published sequences (GenBank) using OMIGA 2.0
software (Genetics Computer Group, Inc. Madison, WI) (Table 1). Optimum
temperatures for primer annealing were determined using a RoboCycler (Stratagene, La
Jolla, CA) with a variable temperature block. Gel electrophoresis of RoboCycler results
confirmed amplification of a single band of the expected size. Transcript levels were then
quantified using the Roche LightCycler (Roche Diagnostics Corp., Indianapolis, IN) and
SYBR green I dye. The annealing temperature was chosen based on the strongest
amplification band in the RoboCycler experiments. Analysis of raw data from the
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LightCycler was standardized by using the Fit Points method, arithmetic baseline, with
the noise band set just below the point at which the second derivative maximum method
calculated highest amplification efficiency. The crossing point was then set at the second
derivative maximum point. Two fit points were used, with the first point below the
crossing point and the second above, for as many samples as possible. Transcription rates
for 18S rRNA were also quantified and used for normalization. For each gene 6
Lightcycler runs were performed. Each run included 3 replicates for both 50 nM and 5
µM Se treatments.
Steady State mRNA Levels
To determine the effects of Se on steady state mRNA levels for each gene of
interest, total RNA was isolated from LNCaP cells treated with 50 nM or 5 µM Se, using
TRIzol reagent (Invitrogen Life Technologies Corp., Carlsbad, CA). Concentration was
determined spectrophotometrically for each treatment and integrity was verified by
agarose gel electrophoresis. Total RNA (5 µg) was reverse transcribed into cDNA and
purified as described above. Primers and annealing temperatures were used as in the
quantitation of nascent transcripts. Quantitation of steady state mRNAs by real time RTPCR for each gene of interest was identical to that described above. Three runs of three
replicates each of both 50 nM and 5 µM Se treatments were performed on the
LightCycler, except for hpS2, for which a fourth run was completed.
Statistical analysis
For electrophoretic mobility shift assays, t tests were used to compare the relative
mean band densities for control and high Se-treated samples.
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Statistical analysis was performed using a randomization test with the
concentrations calculated by the LightCycler software. These calculated concentrations
were compared to those derived using the method of Pfaffl (35) and found to be nearly
identical. To examine relative gene expression, the mean of the replicates of the gene of
interest was normalized by dividing by the mean of the replicates for 18S rRNA. For each
gene the normalized value for the high Se group was divided by the normalized value for
the adequate Se group to give a ratio for relative gene expression.
To determine statistical significance, all replicates of calculated concentrations for
the gene of interest in control Se-treated cells were randomized together with all
replicates for 18S rRNA in the same cells. The same randomization was done with all
replicates for the gene of interest and for 18S in high Se-treated cells. Following this
randomization the same calculations as described above were performed to derive a final
ratio expressing relative gene expression. This randomization and recalculation was
repeated 1000 times, and the number of recalculated ratios greater than and less than the
original calculated ratio were tallied to determine the probability of obtaining the original
ratio simply by chance. The null hypothesis - that the treatment had no effect on gene
expression - would predict an original ratio of 1.0. The only assumption made about the
data was that of independence, as each sample was run in a separate capillary. In this
randomization model no assumptions are made about the distribution of the original
calculated concentrations or the values calculated from the randomized data. A more
detailed description of these statistical methods is in preparation.
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RESULTS
Figure 1 shows typical results from an electrophoretic mobility shift assay.
Densitometric analysis was performed on multiple exposures of three separate EMSA
gels. These analyses showed that the band in the control Se lane accounted for 53.8 ± 6.9
% (mean ± SD) of the total density of the control and high Se bands combined, while the
high Se band accounted for 46.2 ± 6.9% of the total. This difference was not statistically
significant. Disappearance of the band resulting from the addition of unlabeled
oligonucleotide probe to the incubation confirmed the specificity of binding to this probe.
Figure 2 shows the results of the run-on transcription assays. The ratios of
high:control, adjusted for 18S, for IGFBP10, Cdk2, and Cathepsin D are 0.994, 0.880,
and 0.894, respectively. The probability that the ratio of transcription rates (high:control)
was due strictly to random chance for IGFBP10 was 0.385; for Cdk2, 0.347; and for
Cathepsin D, 0.372.
Results from the analysis of steady state mRNA levels for each gene are shown in
Figure 3. The ratios of high:control for IGFBP10, Cdk2, Cathepsin D, and hpS2 are
1.231, 1.108, 1.029, and 1.126, respectively. The probability that the 23% difference in
steady state levels of mRNA between high and control Se samples for IGFBP10 occurred
by random chance was 0.034. For Cdk2, the probability was 0.119; for Cathepsin D,
0.413; for hpS2, 0.196.
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DISCUSSION
Selenium metabolites, such as MSA, are critical for the chemopreventive effects
of Se (6). Ip et al. showed that monomethylated forms of Se cleaved from larger forms,
such as selenocysteine or Se-methylselenocysteine, provide the chemopreventive effects
(16). Cultured cells have low activity of the β-lyase necessary to cleave monomethylated
metabolites from dietary forms of Se, so a monomethylated form must be provided
directly (19). A concentration of 5 µM Se is commonly used in cell culture studies (20,
43, 49), and is between maximum serum achievable levels of Se and average population
values (33). Serum levels of 5 µM can be obtained from a high Se diet or
supplementation.
Ganther has proposed that one mechanism by which Se may reduce cancer risk is
by covalent structural modification of cellular proteins, including transcription factors (8,
9). Others have demonstrated interactions of Se with reactive sulfhydryls in proteins (11),
and we have recently provided evidence consistent with such interaction in the redoxregulated transcription factor NF-kB (41). However, our results in cultured cells do not
suggest as dramatic effects for Se on Zn fingers as those shown by Jacob et al. in vitro
(17). Although their experiments were performed in a reducing environment to match the
state of the cell, Jacob et al. tested phenyl derivatives of Se, which are more stable than
their aliphatic counterparts, but are not as biologically relevant.
Zinc finger proteins constitute as much as 1% of all human gene products (1) and
MSA strongly reacts with zinc-sulfur clusters of metallothionein (MT) (17).
Quantitatively, the concentration of ER is minor compared to other Zn finger-containing
proteins that may react with Se. LNCaP cells express ER-beta at a low level, and express
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little or no ER-alpha (26, 30). It is possible that the MSA used in our experiments
interacted primarily with other, more abundant zinc fingers present in the cell,
diminishing interaction with the ER.
We did find some evidence of interaction between Se and the ER (see Figure 1),
but in this cell line under the conditions used it was minor, or its effects were negated by
other factors. For example, ER binding to DNA requires a number of co-factors. If
everything else is in place, a modest effect of Se on ER Zn fingers may not have been
sufficient to significantly alter DNA binding.
The large number of proteins required for gene transcription in vivo could further
explain why significant down-regulation of estrogen-regulated gene products did not
occur. Such proteins were not present in the experiments of Jacob et al. (17) or the
examination of the ER Zn fingers by Whittal et al. (46). Once such proteins are in place, a
small effect on ER binding may not have been sufficient to significantly down-regulate
gene transcription. Furthermore, although the genes examined are known to be estrogen
regulated, other factors or pathways could also activate their transcription, independent of
estrogen.
Though one significant value resulted from the steady state mRNA assay, there is
uncertainty that a 23 % higher level is biologically significant. As the other genes
examined also resulted in slight, though non-significant, increases, there was likely no
overall biological effect on steady state mRNA levels of the estrogen-regulated genes
examined.
Other studies provide evidence that Se reacts with sulfhydryl groups (17).
However, that reaction, if it occurs in the ER, has a minimal effect on the binding of ER
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to DNA and its regulation of gene expression. Our results are internally consistent.
Without a significant change in DNA binding a significant change in expression of ERregulated genes would not be expected. Our findings do not refute the hypothesis that Se
can alter transcription factor structure and binding to DNA, and therefore regulation of
gene expression. They simply do not provide support for the hypothesis that this
mechanism is operative in the case of the ER in LNCaP prostate cancer cells.
Perspective: Interaction of Se with sulfhydryl groups in proteins can have
significant biological effects. However, in LNCaP cells, the effects of high Se treatment
on the ER and ER-regulated gene expression appear to be minimal. Other transcription
factors whose binding to DNA is dependent on relatively few co-factors, and genes
whose expression is regulated by those transcription factors alone, would be more likely
to be affected by a change in one of the participating factors, such as Se complexing with
reactive sulfhydryl groups. Identifying Zn fingers in such transcription factors or cofactors would allow analysis of Se’s effects while minimizing confounding factors in
vivo. LNCaP cells express ER-beta at a low level, and express little or no ER-alpha (26,
30). Other cell types or cell lines with higher expression of ER might reveal a more
significant effect of Se. Alternatively, other proteins of high abundance, which are known
to react with Se, are more likely to be affected by a change in Se status or availability
(17).
Abbreviations: EMSA, electrophoretic mobility shift assay; ER, estrogen receptor; ERE,
estrogen response element;; MT, metallothionein; MSA, methylseleninic acid.
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Table 1: Estrogen Response Element (ERE) and primer sequences
Gene

Sequence

ERE forward

5'-TAA CTG TCC AAA GTC AGG TCA CAG TGA CCT
GAT CAA AGT TAA TGT A-3'

ERE reverse

5'-TAC ATT AAC TTT GAT CAG GTC ACT GTG ACC
TGA CTT TGG ACA GTT A-3'

18S forward

5'-CGG CTT AAT TTG ACT CAA CAC G-3'

18S reverse

5'-CTA AGA ACG GCC ATG CAC C-3'

IGFBP10 forward

5'-GCC GCC TTG TGA AAG AAA CC-3'

IGFBP10 reverse

5'-CTT GCC CTT TTT CAG GCT GC-3'

Cdk2 forward

5'-CAA GCC AGT ACC CCA TCT TCG-3'

Cdk2 reverse

5'-CAA ATA GCC CAA GGC CAA GC-3'

Cathepsin D forward

5'-GCA AAC TGC TGG ACA TCG-3'

Cathepsin D reverse

5'-ACC ATT CTT CAC GTA GGT GC-3'

pS2 forward

5'-CAG ACA GAG ACG TGT ACA GTG G-3'

pS2 reverse

5'-AGC CCT TAT TTG CAC ACT GG-3'
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FIG 1. Electrophoretic Mobility Shift Assay (EMSA). Lane 1: Probe only. Lane 2: 50
nM Se. Lane 3: 5 µM Se. Lane 4: 50 nM Se + 150x competitor. Lane 5: 5 µM Se + 150 x
competitor. Arrow indicates ER/ERE band. The density of the band in Lane 3 was a nonsignificant 16% lower than the density of the band in Lane 2, based on three separately
run gels with multiple film exposure times for each.
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FIG 2. Run-on transcription assay: Ratio of the mean of the 5 µM Se-treated
replicates divided by the 50 nM Se-treated replicates by gene, each adjusted for
18S rRNA. Bars represent the ratio of the means of LightCycler calculated
concentrations for all replicates as: high (gene)/ high (18S) divided by control
(gene)/control (18S). The probability that the ratio was due strictly to random chance
for IGFBP10 was 0.385; for Cdk2, 0.347; and for Cathepsin D, 0.372. Error bars are not
possible using this statistical model. See text for further discussion.
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FIG. 3. Steady-state mRNA: Ratio of the mean of 5 µM Se-treated replicates
divided by 50 nM Se-treated replicates by gene, each adjusted for 18S rRNA. Bars
represent the ratio of the means of LightCycler calculated concentrations for all
replicates as: high (gene)/ high (18S) divided by control (gene)/control (18S). The
probability that the 23% increase in steady state levels of mRNA for IGFBP10 occurred
by random chance was 0.034. For Cdk2, the probability was 0.119; for Cathepsin D,
0.413; for hpS2, 0.196. * indicates probability <0.05. Error bars are not possible using
this statistical model. See text for further discussion.
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APPENDIX A
LITERATURE REVIEW
Selenium
Selenium (Se), found directly beneath sulfur on the periodic table, is incorporated
into the food chain through plants that incorporate it into cysteine and methionine in the
place of sulfur (11). Se was initially recognized for its toxic effects on livestock
consuming plants of the genus Astragalus, Xylorrhiza, Oonopsis, and Stanleya in the
western part of the United States in 1933 (75). It was recognized as an essential element
for laboratory rats in 1957 (85), followed by sheep and chicken. The requirement of Se
for glutathione peroxidase (GPx) activity in mammals followed in 1973 (81, 91). Se plays
an important role in enzymatic reactions as part of the amino acid selenocysteine
(SeCys). However, Se appears to have anti-tumorigenic activity at levels far exceeding Se
intakes that maximize expression of known SeCys-containing enzymes (46, 72). Part of
the cancer protection seen through the action of Se is derived from Se-dependent GPx's
and thioredoxin reductase (TR) (82). But again, additional benefits are seen at higher
intake levels, suggesting Se supplementation may affect cell cycle regulation, apoptosis,
immune function (57), or carcinogen metabolism (12, 72, 79). Based on the
understanding that Se is beneficial above levels required to maximize the above enzymes,
Se supplementation may be beneficial even in those already consuming adequate levels
of Se in the diet (46, 72). Selenium metabolites, such as methylseleninic acid
(CH3SeO2H, MSA), are critical for the chemopreventive effects of Se (21).
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Dietary Selenium
Dietary Se is consumed as SeCys from animal origin and as selenomethionine
(SeMet) from plant sources (45). Other forms include selenized yeast,
selenohomocysteine, selenocystathionine and Se-adenosylselenomethionine. Selenium
supplementation should begin early in life, and continue for the entire lifespan for
optimal cancer protection (50). Methylation of Se compounds by the body produces less
toxic forms and is the principal means of excreting excess Se (30).
Selenium metabolism
Selenite (H2SeO3) supplementation results in the formation of selenodiglutathione
(GSSeSG). Reduction of GSSeSG by thiols and NADPH-dependent reductases, including
glutathione reductase, releases hydrogen selenide (H2Se) via glutathione selenopersulfide
(GSSeH, 6). It can also be formed through the action of β-lyase on selenocysteine.
Hydrogen selenide is then converted to selenophospate (H3SePO3), making Se available
for synthesis of body proteins (103). Selenomethionine is also incorporated nonspecifically for methionine and is the major form of Se in selenized yeast, used in
chemopreventive studies (98). Se-methylselenocysteine, found in selenized garlic and
other Allium vegetables, is also chemopreventive, with several advantages over
selenomethionine (98). This is likely due to the fact that it is a precursor to MSA.
Different chemical forms of Se have different biological effects. MSA, a
monomethylated low molecular weight Se compound, is a common metabolite of many
anticarcinogenic forms of Se (30). Se-methlyselenocysteine, and other large organic
naturally occurring anticarcinogenic food forms of Se, must be broken down to a
monomethylated form by a β-lyase. However, cultured cells have low activity of the β-
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lyase necessary, so a monomethylated form must be provided directly (49). Selenite, the
standard form of Se used for decades in animal feeding experiments, comprises only a
minuscule percentage of total food Se and its metabolism in the gut and liver makes it
extremely unlikely that cells would be exposed in vivo to this chemical form.
Selenoproteins
The principle form of Se found in mammalian proteins is SeCys (93). It is
incorporated during translation utilizing a UGA codon in the mRNA, normally a stop
codon, with the aid of a hairpin secondary structure in the 3'-untranslated region of the
mRNA (5). In total, 21 selenoproteins have been identified. These include four GPx, two
deiodinases, two thioredoxin reductases and selenophosphate synthetase (1). Other
selenoproteins, such as selenoproteins P and W, are not clearly defined (46).
The first mammalian selenoprotein identified was cytosolic glutathione
peroxidase (GPx1). Not long after, glycosylated plasma glutathione peroxidase (GPx2),
gastrointestinal glutathione peroxidase (GPx3) and phospholipids-hydroperoxide
glutathione peroxidase (GPx4) were discovered. GPx1,2,3 are tetrameric, with one
selenocysteine found on each subunit. GPx4 is a monomer. GPx enzymes reduce
hydroperoxides, such as H2O2, fatty acid hydroperoxides, cumene hydroperoxide,
cholesterol hydroperoxides and t-butyl hydroperoxide (1). After GPx1, type 1
iodothyronine deiodinase (5'DI) was next discovered (72, 93). This enzyme is a
homodimer with one selenocysteine at each of two active sites. 5'DI catalyzes the 5'deiodination of L-thyroxine to tri-iodo-L-thyronine (93). Thioredoxin reductase (TR) is a
Se-dependent homodimeric flavoprotein that reduces thioredoxin in an NADPHdependent manner (1, 5). It can also reduce 5,5'dithiobis-2-nitrobenzoic acid (DTNB) and
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insulin (96). The thioredoxin/TR system reduces ribonucleotides to deoxyribonucleotides,
as well as maintaining redox balance in the cell and regulating the activity of
transcription factors. Selenoprotein P is a Se-containing glycoprotein, providing about a
third of the total selenium in plasma (10). It contains up to 10 SeCys residues and may
have metal binding activity (46), or be useful as a marker for Se status (28).
Selenoprotein W is localized to brain tissue and does not correlate to normal Se
distribution (20).
Se and cancer
Cancer mortality rates for major cancer sites are significantly higher in low
selenium countries (16) and dietary intake of Se correlates inversely with total ageadjusted cancer mortality in 27 countries (7). For hepatocellular carcinoma (HCC), the
group receiving 200 µg of Se yeast showed no cases of HCC, while the placebo group
had seven individuals develop HCC. The study was carried out in 226 hepatitis B antigen
carriers (115).
Se is independently predictive of cancer mortality in a sample of Belgian adult
males, but not females (62). The serum Se levels were already quite high within the
population. High serum Se levels have been associated with reduced risk of prostate
cancer among blacks and whites, especially if serum α-tocopherol levels were low (106).
In breast cancer, low serum selenium levels appear to be the result, not the cause, of
breast cancer (68). A meta-analysis found Se to be protective against lung cancer in areas
where average Se levels are low (117). For women with ovarian cancer undergoing
chemotherapy, Se supplementation increased GPx levels and decreased negative
symptoms associated with the therapy (88). An inverse association between toenail Se
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and colon cancer has also been found, though in the same study, no significant correlation
was found for breast or prostate cancer (32). Significant inverse associations have also
been found between baseline serum Se and death from esophageal squamous cell
carcinoma and gastric cardia cancer (109).
Mechanisms of cancer prevention by Se
The mechanisms for precisely how Se exerts its protective effects have not been
fully explored, though mounting evidence suggests many possible molecular targets (56).
Micromolar levels of monomethylated forms of Se cause apoptosis in p53 null
phenotypes, independent of DNA damage (34). Se also inhibits cyclin dependent kinase 2
(cdk2) and protein kinase C. Ganther (30) proposed Se, particularly monomethylated
forms such as methyl selenol (CH3SeH) and/or MSA, could form Se adducts like
selenotrisulfide (S-Se-S) or selenenylsulfide (S-Se). This could affect cysteine/disulfide
transformations and affect a number of redox regulated proteins, particularly transcription
factors (36, 80). Though its function in in vivo chemoprevention is not well established,
the thioredoxin/TR system is upregulated with Se supplementation in the nutritional to
supranutritional range, but is inhibited if Se causes growth inhibition, presumably by its
actions external to TR. Se shows antimutagenic activity, preventing malignant
transformation of normal cells and activation of oncogenes (50). These effects are likely
due to maximized activity of GPx enzymes, which protect cellular components, including
DNA from oxygen radical damage. Selenoenzymes also have established roles in
carcinogen metabolism, immune system function and oxygen metabolism (50).
Methylated forms of Se also appear to have significant effects on carcinogenesis, and are
required at much lower doses for similar effects than inorganic selenite (31, 89, 93, 112).
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Se-methylselenocysteine or Se-methylselenocysteine selenoxide are cleaved by a β-lyase
to methyl selenol or MSA (2). MSA increases poly (ADP-ribose) polymerase cleavage
and upregulates caspases 1, 3, 6, 7, 8, 10, and 12 toward increased apoptosis in PC-3
human prostate cancer cells. The effect was significantly enhanced when vitamin E
succinate (D-α-tocopheryl succinate) was also added (118). The genes GADD153,
CHK2, p21WAF1, cyclin A, CDK1 and DHFR may be targets of MSA in its role of
impeding cell cycle progression (24). Se may also affect inhibition of cell invasion, DNA
repair and stimulation of transforming growth factor beta signaling (24).
Our laboratory has identified many genes whose expression is differentially
regulated in rats by dietary Se intake (15, 52, 76, 113). These findings have suggested
possible molecular mechanisms for the reported chemopreventive effects of Se against
prostate cancer. Among the genes our lab has shown to be Se-regulated are those for the
estrogen receptors (ERs) (39) and the enzyme estrogen sulfotransferase (EST) (113).
Focusing on Se’s protective effects against prostate cancer, our more recent experiments
in rats showed that dietary Se intake affects blood estradiol concentrations, liver EST
activity, and expression of estrogen receptor beta (ERβ) in the dorsal prostate (39).
Furthermore, the roles of estrogen in prostate cancer have been reviewed (9, 37). Both
animal models and human epidemiological studies have implicated estrogen as a
promoter of prostate cancer (95).
Ganther (30) proposed that one molecular mechanism by which high Se
concentrations may affect cancer risk is by catalyzing disulfide bond formation in cellular
proteins, including transcription factors. Our lab has provided evidence to support this
hypothesis by showing that high Se treatment of LNCaP cells reduces binding to DNA of
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the redox-regulated transcription factor NF-κB, and decreases expression of NF-κBregulated genes. Like NF-κB, ER binding to DNA is strongly influenced by the redox
state of the cell (110). The ER DNA-binding domain contains cysteines in zinc fingers
that are susceptible to oxidation and internal disulfide formation, which prevents DNA
binding. As in NF-κB, high concentrations of low molecular weight Se compounds may
catalyze disulfide bond formation in ER, reducing its binding to DNA and decreasing
expression of ER-regulated genes (29).
Se adduct formation in cysteine residues of proteins inactivates essential thiol
groups of transcription factors and may be a mechanism for the toxic effects of Se (55).
In the presence of protein disulfide isomerase, the addition of selenite (1 µM) resulted in
rapid formation of disulfide bonds in ribonuclease, aiding folding and restoring its
activity in a reducing environment (70). Zinc (Zn) is often complexed between multiple
cysteine residues. The high affinity for Zn of methyl seleno- compounds could remove
the Zn, resulting in disulfide bridges, activating or inactivating enzymes (36). Proteins
shown to be modified by redox mechanisms such as this include protein kinase C (36),
and the transcription factors AP-1 and NF-kB (55, 92). In one case, cells were depleted of
Se, then supplemented from 10-100 nM, with suppression of NF-kB as the dose increased
(71).
Redox control of zinc finger proteins has been recently reviewed by Baldwin and
Benz (4). Dimerization of the ER is required for activity and two Cys4-type zinc fingers
can be found in the DNA-binding domain. Because of these zinc fingers, the ER is
expected to be redox sensitive. Jacob et al. (47) detailed the conditions under which Se
compounds can catalyze the release of zinc from zinc-sulfur coordination sites. Possible
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targets include metallothionein and the ER. Chen and Maret (14) provide additional
evidence of the reactivity of Se compounds in zinc/thiolate coordination sites in
metallothionein. The release of zinc from zinc-sulfur clusters may be an important
chemopreventive mechanism. Other reviewers lend support to the important role of zinc
finger oxidation, focusing on transcription factor proteins (111) and physiological
consequences (108). When zinc is coordinated in the zinc finger, the Cys residues are
more resistant to oxidation, further supporting the unique role of Se compounds to carry
out the oxidation (108). Physiologically, long-term oxidation of zinc fingers, and hence
inactivity, of Sp1 and ER may be the result of lost cellular homeostasis between reactive
oxygen and quenching systems, altering the normally reducing environment of the cell
and explaining certain aspects of aging and ER negative cancers (14).
Prostate cancer
Prostate cancer is the most frequently diagnosed cancer in American men and the
second leading cause of cancer deaths. The American Cancer Society estimates that
prostate cancer will account for 33% of new cancers in men, totaling over 230,000 new
cases, with 29,900 deaths in 2004 (94). Generally arising from prostatic epithelia,
prostate cancer begins androgen responsive, and progresses to an androgen independent
stage. Risk increases with age, obesity, animal fat consumption, red meat consumption,
and among African-Americans, while cereals, vegetables, and vitamin D appear to be
protective (25). However, the European Prospective Investigation into Cancer (EPIC)
study found no correlation between fruits and vegetables and prostate cancer (53).
Giovannucci et al. (33), who found no protective effect for cruciferous vegetables in
older men, did provide some evidence that cruciferous vegetables may be protective early
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in prostate cancinogenesis. Dairy products and calcium are associated with a greater risk
of prostate cancer (13), and androgen levels and reactive oxygen species are also linked
to increased levels (17). On the other hand, moderate to high consumption of fatty fish is
associated with decreased risk (23, 97), and lifetime occupational physical activity may
have a beneficial effect on the occurrence of prostate cancer (3). A traditional Japanese
diet, typically rich in soy-based products and fish, may be protective (90).
Prostate cancer diagnosis
Various methods are utilized in the diagnosis of prostate cancer (83). The earliest
method of identifying asymptomatic prostate cancer was through digital rectal
examination. The test for prostate specific antigen (PSA) in the blood allowed for a
quantitative measurement of prognosis, with higher levels indicating higher levels of
prostate cancer growth or activity (105). Transrectal ultrasonography (TRUS) produces
an image of the prostate using sound waves. TRUS is used in conjunction with prostate
fine needle biopsy to obtain a tissue sample for testing. Fine needle biopsy is also utilized
to test for metastasis in pelvic lymph nodes. A PSA test combined with TRUS and
prostate needle biopsy is the best method for an accurate diagnosis (83). A complete
blood count (CBC) looks for abnormal blood cells to determine if the cancer has spread
to the bone marrow (7). A computed tomography (CT) scan can also be used for prostate
cancer diagnosis, but is not as accurate as TRUS (42).
Prostate cancer treatment
Treatment options include radiation therapy, hormone therapy, chemotherapy, or
radical prostatectomy (22). Radiation therapy targets the prostate and surrounding tissue
with ionizing radiation in an effort to destroy the cancer cells while minimizing normal

34

cell death. Hormone therapy generally targets testosterone or other androgens, via
antiandrogens or castration to abolish hormonal stimulation, which may contribute to
cancer cell growth. Chemotherapy utilizes various drugs given systemically which
interrupt aspects of cell growth, division, or signaling in an attempt to destroy the cancer
cells without killing the host. Treatments are completed in cycles to allow recovery.
Chemotherapy drugs are becoming more specific to cancer, and less toxic to the host.
Radical prostatectomy is the removal of the prostate, effectively eliminating the cancer,
assuming no metastatis had occurred and the operation was successful at removing all
transformed cells. Side effects often include incontinence and/or impotence.
LNCaP prostate cancer cell line
The Lymph Node Cancer of the Prostate (LNCaP) cell line was originally
established (43), and later described (44). LNCaP cells grow slowly, generally in a
monolayer, though with some clumping, and only attach loosely to the substrate. Both the
androgen and estrogen receptors were found to be present. Prostatic acid phosphatase and
prostate specific antigen (PSA) levels were both higher than normal prostate tissue.
Conventional cell culture media typically provide concentrations of antioxidants far
lower than those found in human plasma. This may increase the risk of peroxide-induced
genotoxicity (64). To eliminate this possibility we supplement all cell culture medium
with 50 nM Se and 30 µM α-tocopherol. These concentrations eliminated single strand
DNA breaks induced by H2O2 and maximized the activity of Se-dependant glutathione
peroxidase (GPX, an antioxidant) in the cell lines examined by Leist et al. (64).
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Prostate cancer and Se
Because of its high incidence and long latency period prostate cancer is an ideal
candidate for chemoprevention by dietary means. The Nutritional Prevention of Cancer
Trial showed a marked reduction in prostate cancer incidence in men receiving a daily
supplement of 200 µg selenium (Se) as selenized yeast (17, 18, 20). A protective effect
for Se has been confirmed by other reports that dietary Se intake (84), prediagnostic
serum Se concentration (41, 77, 100), and toenail Se (114) are inversely correlated with
prostate cancer risk.
The thoredoxin/TR redox system, important in cell growth and apoptosis in
prostate cancer cells, requires Se (27, 78). Low serum levels of Se are associated with a
higher risk for prostate cancer (16, 84, 87). Supplemental Se appears to reduce the
incidence (8, 116), and higher levels of Se may even slow the progression of prostate
cancer tumors (66). Many mechanisms have been proposed for Se action in prostate
cancer. These include: oxidative protection (GPx and others), cytotoxic effects,
carcinogen metabolism modulation, apoptosis, angiogenesis inhibition, TR action and
cell cycle regulation (49, 58). Venkateswaran et al. (102) examined four prostate cancer
cells lines, and found Se treatment caused G1 arrest and an 80% reduction of S phase in
LNCaP cells. Se treatment induced the cyclin-dependent kinase inhibitors Cip1/p21 and
Kip1/p27. In each case, androgen dependence was necessary for the effects (102).
Estrogen, Estrogen receptors and the Estrogen Response Element
Estrogen plays an important role in male physiology, affecting brain function,
cardiovascular physiology, bone maturation and resorption, lipid and skin metabolism,
sex interest, and in the aging male, prostate (7, 104). Derived principally from the
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androgen testosterone, estrogens are formed through peripheral aromatization in fatty
tissue (35). Estrogen levels do not decline with age in men (54), and prostate cancer
patients do not have significantly increased or decreased levels of estrogen compared to
normal men (73, 101). However, sex hormone binding globulin increases, decreasing
available estrogen (7, 54). Androgens decrease with age, suggesting the changed
androgen/estrogen ratio may be important, particularly in prostate (7, 54).
The estrogen receptor alpha (ERα) (99) induces transcription of target genes by
binding to promoters of responsive genes. It is a member of a superfamily of transcription
factors that bind to cis-acting enhancer elements in the promoter region (26). ERβ is
highly homologous to ERα in DNA and hormone binding domains, sharing 96 and 58%
homology, respectively (74). In human males, expression is highest in the testis (74).
Both bind 17-β-estradiol with similar affinities. LNCaP cells express ERβ, though at a
low level (67). This expression level is higher than that found in hormone-refractory cell
lines.
Both ERα and ERβ bind to the concensus vitellogenin A2 estrogen response
element (ERE) sequence GGTCAnnnTGACC (59). However, there are many genes
which respond to ERs that differ from the A2 ERE by one or more base pairs (69). ERα
more potently activates promoters containing perfect or imperfect EREs, though ERα and
ERβ have similar affinities for them. The individual ERE differences may account for the
different transactivating effects (69).
Estrogen regulated genes
Several genes are known to be regulated by estrogen in prostate, including
expression in the LNCaP cell line. The genes described below meet both criteria. Cdk2
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(51, 65) is involved in prostate tumor progression and is associated with uncontrolled
tumor cell proliferation, as it is a regulator of the cell cycle. It is more highly expressed in
LNCaP cells than the prostate cancer cell lines PC3 or DU145. Cathepsin D (60, 61) is a
lysosomal protease. It plays a role in cell proliferation and development in prostate
cancer, and is also highly expressed in LNCaP cells. PDL1 (40), a phosphatase important
for signal transduction, removes phosphate groups on serine or threonine residues from a
wide variety of phosphoproteins. HER2 (107), implicated in oncogenesis, is highly
expressed in LNCaP cells. Galectin 1 (40) binds to β-galactosidase in a calciumindependent manner, is highly expressed in LNCaP cells, and plays a role in proliferation,
differentiation, and apoptosis. IGFBP10 (40) is important for growth and proliferation,
one of a family of insulin-like growth factor binding proteins. Se induced a significant
reduction in IGF-1 levels in circulation in rats (38), so thus may affect IGFBP10 levels.
Ha-Ras (60, 86) produces a monomeric GTPase signal transduction protein which is also
an oncogene. hPR (60, 82) encodes the progesterone receptor and is a key mediator of
proliferation and growth in the prostate. HpS2 (48, 63), also known as trefoil factor 1
(TFF1), serves as a marker of malignancy in various cancer types, including prostate
(19). It is expressed in LNCaP cells, and induced by estrogen.
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APPENDIX B
MATERIALS AND METHODS
A list of solutions and buffers, as well as an alphabetic list (by manufacturer) of
purchased reagents can be found at the end of this appendix.
CELL CULTURE
LNCaP cells were maintained in RPMI 1640 with phenol red modified by ATCC to
contain: 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose,
and 150 mg/L sodium bicarbonate.
For treatment, control and high Se flasks were cultured in phenol red free media
otherwise identical to the above, except:
Estrogen levels were brought up to 30 pg/mL.
FBS contained 50 nM Se upon arrival, so automatically provided control levels.
For high Se treatment, methylseleninic acid (MSA) was added for a final concentration of
5 µM.
Cells were placed in the control treatment media for 48 hrs, then the media was
completely changed (5 mL replaced per flask) in control and high flasks, with the high
flasks receiving the extra MSA, for an additional 72 hrs. Cells were then harvested.
Media Formulation
RPMI 1640 (for LNCaP)-phenol red free - 500 mL
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
11.
12.
13.

Put 50 ml of FBS (Fetal Bovine Serum) into 37°C water bath until thawed
(takes approximately 1 hour).
Put 445 ml of deionized water into a 1 L beaker and stir.
Add ½ bottle powdered RPMI 1640 without phenol read and without NaHCO3
(sodium bicarbonate) to beaker. Put a little deionized water into the media
bottle, shake, and add this to the beaker. Mix Thoroughly.
Add thawed FBS to beaker.
Add 0.75 g NaHCO3
Add 1.25 g glucose
Add 1.19 g HEPES
Add 0.055 g sodium pyruvate
Add 5 mL Sigma penicillin-streptomycin antibiotic solution
Add 500 µL 0.03 M α-tocopherol
Add 14.62 µL estrogen (1 µL/mL stock solution) for 30 pg/mL final []
Mix thoroughly
Check pH. Use 1N NaOH or 1N HCl to adjust pH to 7.2-7.3
Use sterile vacuum filters to filter media into sterile media bottles.
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14.
15.

Flame and cap media bottles. Spray with ethanol, let air dry, and then
parafilm.
Label each bottle with RPMI 1640 + FBS (Ph R free), initial and date.

RPMI 1640 (for LNCaP)-with phenol red - 500 mL
1.
2.
3.
4.
5.
6.
7.
8.

Put 50 ml of FBS (Fetal Bovine Serum) into 37°C water bath until thawed
(takes approximately 1 hour).
Remove 55 mL media from ATCC LNCaP growth media (pre-prepared).
Add thawed FBS to media bottle.
Add 5 mL Sigma penicillin-streptomycin antibiotic solution
Add 500 µL of 0.03 M α-tocopherol
Use sterile vacuum filters to filter media into sterile media bottles.
Flame and cap media bottles. Spray with ethanol, let air dry, and then
parafilm.
Label each bottle with RPMI 1640 + FBS (Ph R), initial and date.

Maintenance conditions
Cells were maintained at 37°C in an atmosphere of 5% carbon dioxide and 95% air.
Media was changed every 2-3 days depending on growth and phenol red color change.
The hood was sprayed with 70% EtOH and wiped down (with occasional cleaning with
O-syl), and all instruments and equipment, including gloves, were doused and wiped with
70% EtOH to evaporation. The incubator was cleaned periodically with Roccal. Shelves
can also be autoclaved. Media was filtered before each change using a 30 mL syringe and
a 0.2 µm Acrodisc syringe filter and warmed in the incubator for at least 15 minutes.
Generally all media was removed each time, though some growth benefit may be
obtained by leaving one-third of the old media, replacing two-thirds. Aspirated floating
cells in removed media were spun for 10 minutes at 125xg, then resuspended in 1-2 mL
media per flask. Cells were passaged every one to two weeks, depending on need and
growth. Excess cells were frozen in liquid nitrogen after a slow freeze wrapped in cotton
in complete media plus 5% DMSO. Cells should optimally be cooled at 1°C per minute
(fridge, then -20°C freezer, then -80°C freezer, then stored in liquid N2).
After the initial receipt of cells from ATCC in a 1 mL aliquot, cells were grown in 25
cm2 flasks in 5 mL media. Seven mL of media was added after the cells reached 50-60%
confluence. Cells were passaged 1:2-1:4 depending on need, using 1 mL trypsin/EDTA
solution per flask for a 3 min incubation followed by the addition of 2 mL media to
inactivate the trypsin. Repeated pipetting with 10 mL pipet and electric pipetman to
loosen cells from the flask and another 2 mL media rinse was followed by a 10 min spin
at 125xg. In general, one flask for control and high Se treatment was required for nuclear
protein and RNA isolation. Four flasks of each treatment were used for the run-on
transcription assay.
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Cell Passaging
Materials:
Complete RPMI 1640
10 mL pipettes
0.025% trypsin/ 0.265 mM EDTA solution
culture flasks
waste container
Procedure:
Note: Cells should be passaged at a minimum of 75-80% confluency.
1.
2.
3.
4.

5.

6.
7.

8.
9.

Warm the medium and 0.025% trypsin/ 0.265 mM EDTA solution in
incubator. (Trypsin is stored in 2 mL aliquots in 2 mL microcentrifuge tubes
at -20°C.)
Observe cells and record observations.
Carefully aspirate medium and place in 15 or 50 mL centrifuge tube.
Add 1 mL trypsin to each 25 cm2 flask. Make sure that the bottom of the flask
is completely covered. Incubate in the incubator 3 minutes. Note: To avoid
clumping, do not agitate the cells by hitting or shaking the flask while waiting
for the cells to detach.
Remove flasks from incubator. Add at least 2.0 mL of warmed, filtered (filter
using a 30 mL syringe and a 0.2 µm Acrodisc syringe filter) complete medium
(twice the trypsin). Rinse the side of the flask with the media until all the
cells are removed. Repeat with another 2.0 mL media as a rinse.
Transfer trypsinized cells and media to the 15 or 50 mL centrifuge tube from
step 3.
Centrifuge for 20 min. @ 1000 rpm. Discard supernatant. Add 1 mL fresh
media to centrifuge tube per new flask and pipet with 10 mL pipet ~15 times.
Add to new flasks, 1 mL each. Add 4 mL media to flasks for a total of 5 mL
per 25 cm2 flask.
Subcultivation ratio: 1:2-1:4. Pipet up and down several times so that cells
are dispersed throughout the media.
Label flasks with cell type, subculture number, and date. Return to incubator.

ELECTROPHORETIC MOBILITY SHIFT ASSAY (ref 4)
Nuclear protein isolation
Nuclear extracts were isolated according to the Panomics Nuclear Extraction Kit with the
following modifications:
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1.
2.

3.
4.
5.

6.
7.

8.
9.
10.
11.

Remove culture media from C and H 25 cm2 flasks with 10 ml pipette and
place in two labeled 15 ml tubes. Add 1 ml Clonetics 0.025% trypsin/0.265
mM EDTA to C and H flasks. Incubate in the incubator for 3 minutes.
Add at least 2 ml fresh media to neutralize trypsin. Pipette and wash
repeatedly until all cell clumps are loose from the bottom of the flask. Add
trypsin/cell/media mixture to above tubes. Add 2 ml more to rinse flasks,
wash a few times, and add to original spin tubes. Spin 10 min at 125 g and
pour off media into waste container.
Add 10 ml of PBS, pipette to mix, then spin 10 min. Repeat, pouring off PBS
each time.
Refer to Panomics protocol starting with step two for cell culture, with the
following modifications.
After preparing Buffer A mix, add 500 µL to 15 ml tubes, mix slightly, then
pull pellet and add to labeled (C and H) 1.5 ml Eppendorf tubes. Add the
second 500 µL of Buffer A mix, rinsing to get as many cells as possible from
15 mL tubes, and add to 1.5 ml Eppendorf. Pipette up and down several times.
Continue with 150 rpm shake for 10 min in step 3 of the Panomics protocol.
Use rotating shaker, placing Eppendorf tubes in ice in a 250 mL beaker.
Skip step 4.
In step 9, resuspension is difficult and required repeated vortexing, vertical
sideways, etc. In one case, there was a large clump that would not mix even
after repeated vortexing. It did not appear to interfere with the protein
extraction, as sufficient yield was obtained.
I packed a 250 mL beaker with ice, laid the tubes on their sides on the ice in
one of the metal holders in the rotating shaker next to the -20 C freezer.
The optional step 12 was also completed using the Slide-A-Lyzer dialysis
cassettes and the accompanying protocol. Using an 21 gauge, 1 in needle,
inject the cassette with nuclear extract according to kit instructions.
The cassettes were loaded with the C and H nuclear extracts, labeled, and
placed together in a 100 mL beaker filled with 50 mL Buffer C and left to
dialyze overnight in the fridge.
This protocol was followed by the Bradford protocol to determine protein
concentration.

Bradford protein quantification
1.
2.

Gently mix Bradford reagent in bottle and bring to RT.
Prepare BSA standards of appropriate concentration in the same buffer as the
unknown samples (water can also be used, which we did, according to Sigma
protocol). Create two blanks (water), 5 serial dilutions for the standard curve
and unknowns for C and H selenium treated nuclear extract, all in duplicate,
in 1.5 mL Eppendorf tubes:
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Sample
W1.1
W1.2
S1.1
S1.2
S2.1
S2.2
S3.1
S3.2
S4.1
S4.2
S5.1
S5.2
C1.1
C1.2
H1.1
H1.2

3.

4.

5.

6.

7.

µL H2O
33
33
28
28
23
23
18
18
13
13
8
8
28
28
28
28

µL BSA (1 mg/mL)
0
0
5
5
10
10
15
15
20
20
25
25
5 µL C nuc.ext
5 µL C nuc.ext
5 µL H nuc.ext
5 µL H nuc.ext

mL Bradford reagent
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

5 µL was chosen arbitrarily, as the protein concentration was unknown, but
will generally fit within the curve.
After combining the reagents in 1.5 mL tubes, vortex gently, incubate 10 min.
at RT and transfer to 1 mL polystyrene (for visible wavelengths) cuvettes.
Read at 595 nm using the "fixed λ" function on the Beckman DU 640
spectrophotometer.
Place the water cuvette in the first slot in the six rack, close the cover, and
click 'blank'. Then place the next five cuvettes in, clicking "ReadSamples"
twice. Leave both water controls in each time, changing the other 4, always
reading twice. Print the results, and label by hand.
Using MiniTab, Excel or some other program capable of producing a fitted
line plot and equation, enter in the actual [BSA] for the serial dilution and the
results from the spectrophotometer. Print the resulting graph and equation.
Actual [BSA] in serial dilution:
(1)
5 µL: 1 µg/µL x 5 µL = 5 µg/1033 µL = 0.00484 µg/µL
(2)
10 µL: 0.00968 µg/µL
(3)
15 µL: 0.01452 µg/µL
(4)
20 µL: 0.01936 µg/µL
(5)
25 µL: 0.02420 µg/µL
Using the equation obtained from the graph: Y = AX + B, where Y is the
absorbance, X is the unknown concentration and A and B are given. Compute
the average of the four spectrophotometer readings (two samples, two reads)
for C and H. This is Y. Solve for X in both cases. Multiply this number by
1033 µL and divide by 5 µL, the volume used. The result is the protein
concentration in the nuclear extract in µg/µL.
Aliquot both the C and H protein in 10-15 µL aliquots and store at -80 C.
Repeated freeze/thaw cycles can degrade the protein.
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Estrogen Response Element (ERE) probe
Sequence from Xenopus vitellogenin A2 gene. Estrogen receptor 13-mer palindrome
binding site bolded in forward sequence:
46-mer Forward: 5'-TAA CTG TCC AAA GTC AGG TCA CAG TGA CCT
GAT CAA AGT TAA TGT A-3'
46-mer Reverse: 5'-TAC ATT AAC TTT GAT CAG GTC ACT GTG ACC TGA
CTT TGG ACA GTT A-3'
Preparing radiolabeled probe
1.
2.

3.

Warm the H2O bath to 37°C (cell culture room).
Radiolabel the double-stranded probe:
(1)
Combine the following in a 1.5 mL tube:
2 µL 1 µM double-stranded probe (2 pmoles) (–20°C freezer door)
a) Mix 20 µL of each single strand (50 µM) with 160 µL dH2O in
a 1.5 mL tube (for 5 µM final concentration).
b) Heat to 75°C (in water bath) for 15 min. and allow to cool
slowly (in a beaker with water from the water bath about 30 min.
Store at -20 C)
c) For 2 pmol: dilute 2 µL of 5 µM dsERE with 8 µL dH2O for 10
µL of 1 µM stock solution. Use 2 µL to obtain 2 pmol.
2 µL 10 X PNK buffer (–20°C freezer)
3 µL γ-32P ATP (30 µCi, 10 pmoles)
1 µL T4 kinase (10 units) (–20°C freezer)
12 µL H2O
(2)
Incubate 30 min @ 37°C.
(3)
Dilute reaction mixture to 50 µL with TEN buffer.
(4)
Follow protocol on page 21 of QIAquick nucleotide removal kit
instructions to remove free nucleotides.
(5)
Aliquot 2 µL labeled probe into 2 mL scintillation fluid (under dish
sink) in a scintillation vial and count on scintillation counter (S288
ESC) to determine radioactive incorporation.
(6)
Determine quantities of labeled (1µL) and cold competitor (dilute 5
µM 1:2 for ~150x) to use in binding reaction.
Store labeled probe in –20°C radioactive freezer in a lead pig.

Plate assembly
1.

Assemble clean 16 and 20 cm glass plates, coating one side of one of them
with Sigmacote. Use 1 mm spacers and assemble according to BioRad Protean
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II instructions, ensuring spacers and glass are flush along the bottom. Tighten
down onto one flat gasket only (not two) to minimize leaking.
Prepare 50 mL polyacrylamide gel in liquid form and pour along one
edge/spacer to avoid bubbles (tilting the assembly to one side facilitates this).
If bubbles appear, tap the glass lightly with a hard object (like scissors) until
the bubble rises to the top. Fill to about 1 cm from the top.
Insert 15 well, 1 mm comb, adding extra liquid gel if necessary to fill to the
top. Lay the plates and gel on the side to minimize leaking, if it is occurring.
Wait about 20 minutes for gel to completely solidify.
Gently remove comb and lock gel in Protean II. Pour 0.5x TBE in the top to
ensure there are no leaks and use a pipetman and 10 mL pipet to remove
bubbles in the wells with 0.5x TBE.
Place central apparatus in buffer-filled well, cap, and pre-run at 150 V with
cooling water flowing until mA reach at least 18 (usually starts ~22-24 mA).
This usually requires 1-1.5 hrs.

2.

3.
4.
5.
6.

Binding reaction
1.

Perform binding reaction:
(1) Prepare buffer B gel shift reaction buffer according to García Pedrero,
2002: See below.
(2) In 7 microfuge tubes, add gel shift reaction buffer (fridge), poly(dI-dC) (–
20°C freezer), nuclear extract (–80°C freezer), cold competitor (-20°C
freezer), H2O and antibody according to pipetting scheme below. Incubate
15’ @ 4°C. Add hormone (estrogen at 10-8 M) and incubate at 0°C for 10
min if including this step. Then add probe (small freezer) last and incubate
1 hr at 4°C and 30 min at RT.

SAMPLE

Gel shift
buffer (µL)

Probe1
C2
H3
C4
H5
C6
H7

10
10
10
10
10
10
10

PIPETTING SCHEME:
Poly dI-dC, 150x cold
µg
comp (µL)
1
1
1
1
1
1
1

0
0
0
1
1
0
0

Probe
(pmol
)
0.08*
0.08
0.08
0.08
0.08
0.08
0.08

Nuclear
extract (µg)
0
5
5
5
5
5
5

Antibody
(µL)
0
0
0
0
0
2#
2

H2O
(µL)

Total
(µL)

9
4
4
3
3
2
2

21
21
21
21
21
21
21

* Add probe last.
#Santa Cruz Biotech recommended 1-2 µL of sc-6820X antibody per 3-10 µg protein with
a 15-45 min incubation at RT.
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2.

3.

Run the gel:
(1) Load each sample into separate wells of the gel. Load 10 µL of 1X
bromophenol/xylenol orange blue dye.
(2) Electrophorese @ 100 V (18 mA decreases to 10 or less) ~2 hrs (limits
overheating, U shape, and gives sharper bands) until dye front is 2-3 cm
from the bottom of the gel, in 0.5x TBE (within the gel and for the running
buffer).
(3) Remove and separate plates gently, leaving the gel on one plate. Place
moistened Whatman paper on gel, then gently peel from one corner, then
from one edge until separated from the second glass plate, taking care not
to twist, warp, or tear the gel.
(4) Dry gel @ 80°C under vacuum 60 min. Place plastic wrap on gel surface
prior to covering with hard plastic and flexible silicone seal on flat dryer.
Expose dried gel to film (dark room) as long as is needed depending on the
age of the radioactivity (1-18 hrs). Place dried gel in lead-lined, lightexcluding case, taping down if drying caused curling. Place 1-2 sheets of film
on the gel in the dark (do not turn on red light if possible) and close the case.
Place case in the -80°C freezer and expose the necessary time. Develop film in
automatic developer in dark room after allowing it to warm up (~15-20 min.,
press the 'run' button after turning on the power).

RUN-ON TRANSCRIPTION ASSAY (ref 2)
Preparation of nuclei
1.
2.

3.

Pellet up to 1 x 107 cells and wash twice with PBS as above for nuclear
protein preparation. I used four confluent 25 cm2 flasks for both C and H.
Follow Panomics Nuclear Extraction Kit protocol with above modifications
for nuclear protein isolation up to step seven, completing only the wash with
Buffer A Mix. Remove cytosolic protein. Panomics confirmed after this step
that nuclei remained.
Resuspend pellets in 1 mL glycerol storage buffer for nuclei and store at 80°C.

In-vitro RNA synthesis
1.

2.

Gently add 1 volume (100 µL) of 2X transcription buffer to nuclei on ice after
adding 2 µL RNaseOUT to top of pellet. Adding 100 µL will make the ATP,
CTP, and GTP concentrations each 5x that of the 8 µL biotin-16-UTP. Add 8
µL biotin-16-UTP. Incubate 30 min. at 29°C.
To stop reaction, add 6 µL 250 mM CaCl2, 6 µL RNase-free DNase I and
incubate for 10 min at 29°C.
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RNA isolation (Invitrogen protocol) (ref 1)
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

11.
12.
13.

Transfer above reaction to new 15 mL conical tubes, using part of Trizol in
step 2 below to rinse 1.5 mL tubes used in in-vitro RNA synthesis.
Add 2 mL Trizol reagent and lyse nuclei by repetitive pipetting until no longer
visible.
Incubate the samples for 5 minutes at room temperature.
Add 0.2 ml CHCl3/1ml Trizol. Shake tubes vigorously by hand for 15
seconds.
Incubate CHCl3 samples for 3 minutes at room temperature.
Centrifuge samples for 15 minutes at 12000xg at 2-8°C.
Pipet as much of the aqueous phase as possible into fresh 15 mL tubes. Add
0.5 ml 2-propanol/1 ml Trizol to each sample.
Incubate 2-propanol samples for 10 minutes at room temperature.
Centrifuge samples for 10 minutes at 12000xg at 2-8° C.
Remove supernatant. Add 1 ml 75% EtOH/mL Trizol to all samples. Vortex
samples and centrifuge for 5 minutes at 7500xg at 2-8°C. Vortexing may only
separate pellet into smaller chunks, it does not dissolve, as this is a washing
step.
Pour out 75% ETOH, and allow samples to dry in upside-down tubes for 1015 minutes. Wipe residual alcohol out of tubes with a kimwipe and spatula.
Dissolve RNA pellet in 50 µL DEPC-treated water.
Allow to dissolve. Transfer to 1.5 ml tubes and put on ice or in
–80°C freezer as quickly as possible.

Binding to magnetic beads
1.

2.

3.

4.
5.
6.
7.

Wash 100 µL of Dynabeads M-280 in Dynal Solutions A (two 100 µL washes
for 1-3 min.), B (one 100 µL wash) and binding buffer (one 100 µL wash)
according to instructions for use for RNA manipulation and nucleic acids
immobilization procedures provided with the Dynabeads.
Resuspend 100 µL of Dynabeads M-280 in binding buffer at full
concentration (10 µg/µL). I also added 1 µL of RNaseOUT to each of the two
tubes. Aliquot 50 µL to each of two tubes for C and H RNA.
Mix resuspended beads with an equal volume (50 µL) of run-on RNA and
incubate 20 min. at 42°C and 2 hours at RT. Beads collected on the bottom of
the tubes, though this will not affect results. Enzymes and RNA are much
smaller than the beads.
Separate beads with the magnetic apparatus supplied by Dynal.
Perform two 15 min. washes in 500 µL 15% formamide in 2X SSC, meaning
resuspend beads in the wash and allow to incubate at RT, then place in magnet
and remove wash. Repeat.
Wash 5 min. in 1 mL 2X SSC.
Resuspend beads in 30 µL DEPC-treated H2O and store at –20°C. This
required some pipetting, as beads were high on the wall of the tube from the
last wash.
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cDNA synthesis
cDNA synthesis was performed in triplicate, using 10 µL of the above 30 µL final
volume for both C and H, for a total of 6 tubes.
1.

2.
3.

4.
5.
6.
7.
8.
9.
10.
11.
12.

Combine the following in a 500 µL tube, 1 tube per sample:
1.0 µL random hexamers (50-250 ng)
10 µL run-on RNA (10 µL max)
1 µL 10 mM dNTP Mix (10 mM each dATP, dGTP, dCTP, and
dTTP at neutral pH)
ddH2O to 12 mL
Incubate at 65°C for 5 min. Plunge in ice 2-3 min., spin down condensate
briefly.
Add:
4 µL 5X first strand buffer
2 µL 0.1 M DTT
1 µL RNaseOUT (40 U/µL)
19 µL total reaction volume
Mix contents gently (resuspend the beads with gentle stirring).
Incubate at 25°C for 2 min for random hexamers.
Add 1 µL (200 units) SSII Reverse Transcriptase, mix thoroughly by pipetting
gently up and down.
Incubate at 25°C for 10 min (added incubation for use of random hexamers,
instead of oligo dT12-18 (500 µg/mL)).
Incubate at 42°C for 50 min.
Inactivate enzyme by incubating at 70°C for 15 min.
Add 1 µL (2 units) Rnase H, mix thoroughly.
Incubate at 37°C for 20 min.
Recombine the 3 C and 3 H tubes into one again, for a total of 63 µL each.

Qiagen PCR purification kit columns (Qiagen protocol)
4.
5.
6.
7.
8.
9.
10.
11.
12.

Combine 5 volumes of PB buffer with 1 volume of the PCR sample and mix.
Place QIAquick spin column in a provided 2 mL collection tube.
Apply the sample to the column. Centrifuge 1 min. @ 13,000 RPM on
standard tabletop microcentrifuge.
Discard flow through and place the QIAquick column back in the same tube.
To wash, add 750 µL Buffer PE to the column and centrifuge 1 min.
Discard flow through and place the column back in the same tube. Centrifuge
the column for an additional 1 min at 13,000 RPM.
Place QIAquick column in a clean 1.5 mL centrifuge tube.
Elute DNA with 50 µL EB buffer (10 mM Tris-HCl, pH 8.5) to the center of
the QIAquick membrane and centrifuge @ 13,000 RPM for 1 min.
Add another 50 µL H2O to each tube for a total of 100 µL.
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13.

Store cDNA at –20°C until ready for use.

Primer Design
1. Find Gene Sequence of Interest
a) This can be done several ways:
i) Go to the Entrez-PubMed website (www.pubmed.gov)
(1) Click on “Nucleotide” on the black toolbar at the top of the screen
(a) Type in the name of the gene of interest and a list of several matches
(hopefully) will come up. Make sure to pick a sequence for the species
of interest (homo sapien, etc.) and that match genes you are looking
for. The number that the gene is listed as is called the accession
number and it can be used to search for a particular sequence in any of
PubMed’s applications. Oftentimes several accession numbers will be
found for the same gene that are all okay to use.
(b) It is also possible to click on “Search for Genes” which is found in the
blue column on the left-hand side of the Entrez-PubMed website. This
will allow searches for genes using LocusLink.
(i) Type in the name of the gene of interest and a list of several
matches (hopefully) will come up just like above. Use the same
criteria to pick the gene of interest. Also, LocusLink allows
searches in a specific organism’s genome.
(2) After getting to the Entrez-PubMed home page, do a search in PubMed
using the name of the gene of interest (This is a much longer process).
This will bring up several articles with the gene of interest listed as a
keyword.
(a) Refine the search to “’name of gene of interest’ AND ‘name of
protocol”.
(b) Filter through these articles and find articles that have used primers for
the gene of interest. Articles may be listed that have the primer
sequence listed in the article. This takes a long time because access is
often denied to certain journals/full-text articles online.
(c) Primers from articles can be used a couple of ways:
(i) If the article states the bp length of the fragment that will be
amplified using the primers found, then check that their primers
will amplify a region of the right gene sequence. Check the primers
using BLAST (instructions below).
(ii) If the article doesn’t state the bp length of the fragment that will be
amplified using the primers found then just take the primer
sequence and enter it into BLAST to find accession numbers of the
gene of interest (instructions below).
(3) Using BLAST:
(a) To verify if a primer sequence will sit down on the correct gene, use
BLAST. After entering in the primer sequence, BLAST gives a list of
all of the different genes (labeled with different accession numbers)
that the primer sequence will sit down on.
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(i) Go to the GenBank website.
(ii) Click on “BLAST” on the black toolbar at the top of the screen.
(iii) Click on “Standard nucleotide-nucleotide BLAST [blastn]”
(iv) Type the primer sequence into the box that has “Search” to the
left of it.
(v) Click on the blue “BLAST!” button.
(vi) Click on the blue “Format!” button.
(vii)
A list of several genes that the primer matches will come
up after waiting a bit. Use this list of genes to either verify that the
primers will sit down on the right gene or to find accession
numbers for the gene of interest. BLAST lists the genes according
to an “E-value.” This E-value corresponds to how complimentary
the primer sequence is to a particular gene. Try to use sequences
with E-values of .05 or lower.
2. How to Download Gene Sequences into OMIGA for Primer Design:
a) Upon obtaining accession numbers for the genes of interest, click on the accession
number (if it is on the screen), or enter the accession number into any of
PubMed’s applications and the accession number link will come up.
b) Upon clicking on an accession number, a taxonomy report will come up on that
particular gene.
c) Click on the down arrow of the box that says “default” and change it to
“GenBank” (this box is found next to the box that says “Display” and is on the
toolbar at the top of the screen).
d) Now click on “Save.” This will save the gene in the GenBank format so that
OMIGA can read the file when importing it into OMIGA.
e) A “File Download” textbox will come up. Click “OK” to save the file to a disk.
f) Rename the file and save it on any hard drive. Make sure to save it as an “.fcgi”
file type. It is best to name the file as the name of the gene of interest followed by
the accession number. It may be necessary to import several sequences for the
same gene and being as specific as possible in naming the file when saving it
makes it easier later.
g) Once the gene sequence is saved on the hard drive, then open OMIGA by going to
“Start” then “Programs” then “Omiga” then “OMIGA.”
h) Open a new project in OMIGA or open an existing project.
i) Once in OMIGA, then click on “File” then “Import.”
j) Find the gene that was saved on one of the hard drives and double click on it.
k) An “Import As Format” textbox will automatically come up. OMIGA will
highlight the file format that it recognizes (it should automatically highlight
“GenBank Nucleic Acid Format” because it was saved as a GenBank file). Click
on “Import.”
l) A “Name Sequence File” textbox will come up. Enter in a name for the sequence
here. When naming the sequence here there is no need to be specific. Just name
thesequence as its common name. Name all imported sequences for a given gene
the same name. After naming the sequence click on “OK.”

66

m) The sequence is now imported into OMIGA. From here use the downloaded
sequences to design primers.
3. Primer Design in OMIGA:
a) Open the project in OMIGA.
b) If more than one sequence for a given gene has been imported, then it is important
to align the gene sequences to identify any differences between them. Do this by
highlighting all of the gene sequences needed for the comparison (using the Ctrl
key) and by clicking on the “Align Sequences” icon at the top of the toolbar
(alternatively, go to “Calculate” and then “Align Sequences.”) A “Clustal W
Alignment” textbox will come up. Click on “Align.” A “Save Alignment File”
textbox will come up. Save your alignment (save it as the name of the gene you
are working with). Make sure to save it as an “.ali” file type.
i) A “Calculation Progress-Clustal Alignment Progress” textbox will come up.
As soon as the alignment is visible, click on the “Alignment” button.
ii) If there are any ambiguities in the sequences, the “Consensus” sequence will
show a gray base. Pick the gene sequence that is the least different from the
other sequences to design the primers. There is also the option of using the
Consensus sequence to design the primers, but it is easier to just pick one of
the sequences already downloaded.
c) Now that the sequence that you would like to use has been chosen, design the
primers. Highlight the sequence to use by clicking on it. Then click on the “PCR
Primer Pairs” icon which is found on the top toolbar (or you can go to “Search”
and then “PCR Primer Pairs.”)
i) A “Search- PCR Primer Pairs” icon will come up. Create new search
parameters (click on “New…”). Name the protocol in the upper left-hand
corner.
ii) For Real-Time PCR, BioRad recommends the following parameters in
designing primers:
(1) On the “Individual Primers” tab, set the Length (bp) to 18, 20, 22. Set the
% GC Content to 50, 55, 60. Set the Tm (C) to 50, 58, 65. Leave the 3’
clamp residues on and at WSS. (S is code for a G or a C; W is code for an
A or a T). The clamp will ensure that on the 3’ end of the primers will
have an A or T, then a G or C, then a G or C. Leave all of the other
parameters as they are.
(2) On the “Primer Pairs & Products” tab, set the Length (bp) to 75, 110, 150.
Set the % GC Content to 50, 55, 60. Leave the Tm (C) at 70, 82.5, 95.
Leave all of the other parameters as they are.
(3) When finished adjusting the parameters, click on “OK.” Then click on
“Search.” When your primer search is complete, view the primers in a
table by clicking on “Table.” This will show a table of all of the possible
primers based on the criteria you specified.
(4) If the search failed, that means that OMIGA could not design any primers
using the parameters specified. If this happens, then decrease the
stringency of the parameters. Start with decreasing the %GC content on
either tab (“Individual Primers” or “Primer Pairs & Products”). If the
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search fails again, then change the 3’ clamp to “SS” rather than “WSS.” If
the search fails again, then take off the 3’ clamp altogether. If the search
still fails, then slightly change any parameters to help design the primers.
If it is this difficult, the primers will probably not be optimal during PCR
reactions.
(5) If the search does fail, view the “Table” of all possible primers anyway. At
the bottom of the textbox there are two other tabs called “Rejected
Primers” and “Rejected Pairs.” On these two tabs, OMIGA will list all of
the primers that were considered and the reasons they were rejected. This
can help to decide which parameters to change.
(6) The region of the gene on which to design primers can also be specified.
At the bottom of the “Search-PCR Primer Pairs” textbox, click on
“Include bp region” and specify the desired starting bp and ending bp.
Using this feature drastically limits the number of possible primers. If your
searches are consistently failing, it may help not to specify a specific
region of the gene.
Human Primers used for Run-on Transcription Assay and total RNA RT-PCR
18S Forward: 5'-CGG CTT AAT TTG ACT CAA CAC G-3'
18S Reverse: 5'-CTA AGA ACG GCC ATG CAC C-3'
Cdk2 Forward: 5'-CAA GCC AGT ACC CCA TCT TCG-3'
Cdk2 Reverse: 5'-CAA ATA GCC CAA GGC CAA GC-3'
Cathepsin D Forward: 5'-GCA AAC TGC TGG ACA TCG-3'
Cathepsin D Reverse: 5'-ACC ATT CTT CAC GTA GGT GC-3'
IGFBP10 Forward: 5'-GCC GCC TTG TGA AAG AAA CC-3'
IGFBP10 Reverse: 5'-CTT GCC CTT TTT CAG GCT GC-3'
pS2 Forward: 5'-CAG ACA GAG ACG TGT ACA GTG G-3'
pS2 Reverse: 5'-AGC CCT TAT TTG CAC ACT GG-3'
Robocycler runs to determine optimum annealing temperatures
Use the following protocol for each set of primers above with control cDNA made from
total RNA. Optimal annealing temperatures will be used for both Run-on Transcription
Assay and total RNA gene expression determinations.
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Assemble the following into an ice bucket:
Taq polymerase
10 X buffer
dNTP mix (10µM) or PCR nucleotides
cDNA pool (dilute about 1:6)
Primers (10µM each)
MgCl2
Purified H2O
1.
2.
3.

Protocol:
Label a 1.5 ml tube MM for Master Mix.
Label 12 PCR tubes with letters coordinating to the primers used and number
them starting with 1 through 6 for two sets of primers
Add each reagent according to the table below starting with the smallest
amount to the largest. If using different primers see below.

Taq

1 Rxn
0.2 µl

8 Rxn
1.6 µl

15 Rxn
3 µl

dNTP mix

0.4 µl

3.2 µl

6 µl

Primers (10µM each)

1.0 µl

8.0 µl

*see below

10 X buffer

2.0 µl

16.0 µl

30 µl

cDNA

0.8 µl

6.4 µl

12 µl

MgCl²

2.4 µl

19.2 µl

36 µl

H²O

13.2 µl

105.6 µl

198 µl

20.0 µl per tube

160.0 µl =20 µl/
8 Rxn
tube

285 µl =19 µl/
15 Rxn tube

4.
5.
6.
7.*

8.
9.
10.

Vortex each reagent before adding it to the master mix, with the exception of
the Taq enzyme. After adding each ingredient, pipette the master mix up and
down gently.
Once master mix is complete, centrifuge for 5 seconds.
Dispense 19µl into of master mix into each PCR tube.
Dispense 1µl of primers (10 µl each) into each tube according to how many
primers are being sampled. All samples of the same primer should be
uniform. If there is no variation of primers add 15µl of primers to the master
mix, dispense 20µl into each tube and skip this step.
Centrifuge tubes for approx. 5 sec. at a high speed.
Add approx. 20 µl of mineral oil to the top of each tube.
Centrifuge briefly so mineral oil lies on top of sample layer
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To Run Robocycler:
1.
2.
3.
4.

5.

Flip the switch located on the back of the machine. Wait until the computer
screen illuminates and the welcome screen comes on.
Hit the shift key + 9 (recall program) and recall program #01.
Hit the shift key + 1 (set gradient) and choose desired gradient.
If necessary, you can use the arrow keys to manually change the values in
each window. Be sure to match the annealing gradient in window 1 to the
values in window 2, or the annealing gradient block will not be at the correct
temperature for the first few cycles.
Once all the temperature and cycles are checked to match the table below, hit
RUN/STOP and the blocks will heat up. Once the blocks are heated load your
samples according to the temperature variation desired and hit ENTER.

RoboCycler Temperatures
Cycles
1 (window 1)

Time
4 minutes

Temperature
95°C

35(window 2)

30 seconds
30 seconds
45 seconds

95°C
Annealing Gradient
72°C

1 (window 3)
1 (window 4)

7 minutes
indefinite

72°C
6°C

Determining Annealing Temperature
1.
2.
3.
4.
5.
6.

Pour a 2% agarose mini gel with a 7 tooth comb and allow it to harden.
Add 4 µL of 6x Loading dye to each sample and mix for a total of 24 µL. Spin
briefly.
Add 10 µL to each well and 3 µL 100 bp ladder to the last lane.
Run in 1x TAE buffer at 100 V for ~60 minutes until dye front is 1 cm from
the bottom.
Soak gel 10 min in Ethidium Bromide, then 10 min in water. Visualize, label
and print on Alpha Imager. Expose at about 1-1.5 sec, adjusting black and
white until a good picture of your bands is visible.
Use the temperature at which the band is the brightest for the annealing
temperature in LightCycler runs.
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LightCycler Run
1.

2.
3.

Assemble the following into an ice bucket:
Taq polymerase
10 X buffer
dNTP mix (10 µM) or PCR nucleotides
cDNA:
undiluted pool (10 µL C and 10 µL H)
1:2 pool (10 µL undiluted and 10 µL dH2O)
1:4 pool (10 µL 1:2 and 10 µL dH2O)
1:8 pool (10 µL 1:4 and 10 µL dH2O)
1:16 pool(10 µL 1:8 and 10 µL dH2O)
C Se 1:6 dilute (2 µL cDNA and 10µH2O)
H Se 1:6 dilute (2 µL cDNA and 10 µL H2O)
SYBR green 1:2000 dilute (add 1 µL 10000x to 49 µL H2O for 1:50, then
1 µL of 1:50 dilute to 39 µL H2O for 1:2000 dilution)
Primers (10µM or 25 µM each)
MgCl2
BSA (1 mg/mL)
Purified H2O
Label a 1.5 ml tube MM for Master Mix
Add each reagent according to the table below starting with the smallest
amount to the largest. With the exception of the SYBR green which is to be
diluted and added in after the H2O and the cDNA which will be added
individually at the end.

Taq

1 Rxn
0.16 µl

dNTP mix

0.40 µl

Primers (10µM each)

20 Rxn
3.2 µl
8 µl

1.00 µl (10 µM) or 0.40 µl (25 µM) 20 µl or 8 µl

10 X buffer

2.00 µl

40 µl

cDNA

2.00 µl

*add individually

MgCl²

3.20 µl

64 µl

BSA

5.00 µl

100 µl

H²O

5.10 µl or 5.70 µl

102 µl or 114 µl

SYBR green (1:2000 dilute)

1.14 µl

22.8 µl

360 µl =18 µl per cap.
20 Rxn (2 extra)
Vortex each reagent before adding it to the master mix, with the exception of
the Taq enzyme. After adding each ingredient, pipet the master mix up and
down gently.
Once master mix is complete, centrifuge for 5 seconds.
20.00 µl per capillary

4.
5.
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6.
7.
8.

Place 18 capillaries in the LightCycler centrifuge adaptors.
Dispense 18 µl of the MM into each capillary.
Dispense 2 µl of cDNA into each capillary coordinating to the numbers
below.
1) 1:1 cDNA pool
2) 1:1 cDNA pool
3) 1:2 cDNA pool
4) 1:2 cDNA pool
5) 1:4 cDNA pool
6) 1:4 cDNA pool
7) 1:8 cDNA pool
8) 1:8 cDNA pool
9) 1:16 cDNA pool
10) 1:16 cDNA pool
11) C Se 1:6 dilute
12) C Se 1:6 dilute

9.
10.
11.

13) C Se 1:6 dilute
14) H Se 1:6 dilute
15) H Se 1:6 dilute
16) H Se 1:6 dilute
17) H2O
18) H2O

Centrifuge capillaries in their adaptors for 30 sec at 2500 rev/min.
Cap each capillary with white cap.
Gently twist capillaries into LightCycler capillary holders, starting with
number 1 on the carousel. THEY EASILY BREAK!!

To run LightCycler
1.
2.
3.
4.
5.
6.
7.
8.

Double click on NEW LIGHT CYCLER SOFTWARE 3.5.3
Click RUN on main menu
Allow machine to self test, once finished click OK.
Go to file and click open. Select program and click OPEN.
Under Experiment, click on Amplification. Adjust the middle Target
Temperature to desired annealing temperature.
Change setting/names of carousel slots as needed under Edit Samples,
depending on whether it is a standard, unknown, or negative control.
Click RUN and save experiment.
After amplification, once the flow reaches about 100 or the graph starts to
slope off click END PROGRAM and allow machine to go to next program,
melting curve analysis. DO NOT click on EXIT RUN.

Quantification
Once experiment has finished, Data Analysis will automatically open.
1.
2.

At the top left click on Select a Program and choose Melting Curve Analysis.
Choose Melting Curve on the top of the screen. Check to make sure all DNA
denatured at the same temperature and that there is only one peak on the
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3.
4.
5.

6.

7.
8.
9.
10.

11.

12.

bottom graph. Deselect those that have additional peaks (primer dimers), and
print the results (Ctrl-P).
Close that screen and click on Select a Program again. Choose Amplification.
On the top of the screen click Quantification.
The program defaults to Second Derivative Maximum (SDM) method. Select
sample #1 only. Using two straight edged instruments, such as rulers, line up
vertically at the crossing point for the selected sample with one ruler and
horizontally with the other ruler from the point of amplification to determine
the fluorescence at which the second derivative was at its maximum for that
sample.
Repeat for all other samples individually until you have, hopefully, a
consensus. Remember or write down any samples that do not have a similar
fluorescence as the others. They should be in the range of 0.5-1.0 fluorescence
different from the others, either up or down.
Select Fit points and check Step 3: Analysis. Ctrl-deselect any samples that
had more than one peak in the Melting Curve analysis.
Select Step 2: Noise Band and adjust the Noise Band line a few tenths of
fluorescence below the optimal value you determined in the SDM analysis. It
should be in the amplification phase of the run.
Select Step 3 again and set the fluorescence band right at the value determined
by the SDM method. Also check the 'Show Fit Points' box, but leave the
number of points at 2.
With the 'Show Fit Points' box selected, cross marks will show which
measurement points the program is using to determine the slope. The
fluorescence band should be between these two fit points for as many samples
as possible. If not, return to Step 2 and adjust the noise band until the
fluorescence band, at maximum SDM efficiency, lies between all or nearly all
fit points. Be sure to re-adjust the fluorescence band when you return to Step
3, as it will move when you move the noise band.
Carefully look at your samples and replicates, remembering which SDM
points were not like the others. If a Calculated Concentration is very different
from its replicates, or a point on the standard curve is way off, hopefully the
SDM point was also different, giving you more leverage to eliminate that
point. Your goal is to get an r-value of at least -0.95 or closer to -1.0, and as
many matching replicates as possible in your unknowns.
Use Ctrl + P to print the window, making sure the screen shows all of the
Grouped Means, Calculated Concentrations and Crossing Points.

TOTAL RNA RT-PCR
RNA isolation from LNCaP cells
1.

RNA was isolated as above, according to the Invitrogen protocol, except that
2.5 mL TRIzol was used per 25 cm2 flask, and the RNA pellet was redissolved in 100 µL RNAse free H2O per 1 mL TRIzol.
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RNA quantification
Quantification of RNA using spectrophotometry allows you to determine how much
RNA you have isolated as well as how free of protein contaminants it is.
1.

Make sure that spectrophotometer is on. The UV lamp must be turned on and
must have 10 min. to warm up. It must have a chance to cool for at least
45min before being turned on again.

2.

Use Beckman capillaries for UV readings. One capillary is for each sample. A
'blank' cuvette will contain only water. Use the capillary holder in the single
rack. Optimal position was found to be at 56.1 mm.

3.

Pipet 7 µL of each sample onto a weigh boat and use capillary action to draw
the sample into the capillary (the capillary holds about 5 µL). Seal with a
small amount of Critoseal and wipe clean a few times with a Kimwipe. Repeat
for each sample.

4.

Take cuvettes to spectrophotometer. Select 'nucleic acids.'
o
o
o
o
o
o

Open lid and place BLANK cuvette (containing water only) in capillary
holder.
Close the lid.
Press the 'Blank' button. Wait for display to stabilize at 0.000. Click
'ReadSamples' a few times.
Open the lid. Remove blank and place sample in holder.
Close the lid. Click 'Readsamples' a few times until the numbers stabilize
or rise and fall so an average is obtained.
Repeat for other samples.

5.

Calculate the 260/280 ratio. A 'very clean' sample will have a 280/260 ratio of
between approximately 1.8 and 2.0. Alternatively, a 280/260 should be
between 0.4 and 0.55.

6.

Calculate the concentration of RNA in each sample using the following
equation. (Note that the equation only uses the OD260.)
[µg/µl] = [(OD 260) - (OD 320)] * 0.8
bold= conversion coefficient for RNA

cDNA Synthesis
Carried out as above for Run-on Transcription Assay, except the cDNA was diluted from
48 µL after the Qiagen clean-up to 192 µL (added 48 µL H2O, then 96 µL H2O) to ensure
enough supply for all LightCycler runs.
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RoboCycler and LightCycler runs
Both were carried out as above. For the RoboCylcer, optimum annealing temperatures
were determined for all genes using total RNA-produced cDNA, whether the primers
were used here or for the Run-on Transcription Assay. LightCycler protocol is the same,
except that cDNA from total RNA was used.
Statistical Analysis
For EMSAs, t tests were used to compare the relative mean band densities for control and
high Se-treated samples.
Statistical analysis was performed using a randomization test with the concentrations
calculated by the LightCycler software. These calculated concentrations were compared
to those derived using the method of Pfaffl (3) and found to be nearly identical. To
examine relative gene expression, the mean of the replicates of the gene of interest was
normalized by dividing by the mean of the replicates for 18S rRNA. For each gene the
normalized value for the high Se group was divided by the normalized value for the
adequate Se group to give a ratio for relative gene expression.
To determine statistical significance, all replicates of calculated concentrations for the
gene of interest in control Se-treated cells were randomized together with all replicates
for 18S rRNA in the same cells. The same randomization was done with all replicates for
the gene of interest and for 18S in high Se-treated cells. Following this randomization the
same calculations as described above were performed to derive a final ratio expressing
relative gene expression. This randomization and recalculation was repeated 1000 times,
and the number of recalculated ratios greater than and less than the original calculated
ratio were tallied to determine the probability of obtaining the original ratio simply by
chance. The null hypothesis - that the treatment had no effect on gene expression - would
predict an original ratio of 1.0. The only assumption made about the data was that of
independence, as each sample was run in a separate capillary. In this randomization
model no assumptions are made about the distribution of the original calculated
concentrations or the values calculated from the randomized data. A more detailed
description of these statistical methods is in preparation.
REFERENCES--MATERIALS AND METHODS
1. Chomczynski P and Sacchi N. Single-step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:
156-159, 1987.
2. Patrone G, Puppo F, Cusano R, Scaranari M, Ceccherini I, Puliti A, and
Ravazzolo R. Nuclear run-on assay using biotin labeling, magnetic bead
capture and analysis by fluorescence-based RT-PCR. Biotechniques 29: 10121014, 1016-1017, 2000.
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3. Pfaffl MW. A new mathematical model for relative quantification in real-time
RT-PCR. Nucleics Acids Res 29: 2002-2007, 2001.
4. Wang YC and Montalvo EA. Analysis of DNA binding proteins by mobility
shift assay. Methods Mol Biol 174: 289-296, 2001.
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SOLUTIONS AND BUFFERS
Pedrero Buffer B
1 M HEPES-KOH (pH 7.9, adjusted with KOH, 15 mL, 3.575 g HEPES in H2O made
separate)
2 M KOH (15 mL, 1.683 g KOH in H2O made separate)
0.020 M HEPES-KOH, pH 7.9 (300 µL above)
0.01 M MgCl2 (0.0143 g)
0.001 M EDTA (30 µL 0.5 M)
0.1 M KCl (0.112 g)
0.0002 M phenylmethylsulfonyl flouride (0.000523 g)
0.0002 M DTT (30 µL 0.1 M)
0.5% Nonidet P-40 (75 µL)
10 % glycerol (1.5 mL)
protease inhibitors (~15 µL)
Bring up to 15 mL with dH2O
PBS
10x stock solution:
1370 mM NaCl (80 g)
27 mM KCl (2 g)
43 mM Na2HPO4·7H2O (11.5 g)
14 mM KH2PO4 (2 g)
Bring up to 1 L with d H2O, ensuring pH is ~7.4, then filter sterilize
PBS (500 mL):
137 mM NaCl (4 g)
2.7 mM KCl (0.1 g)
4.3 mM Na2HPO4·7H2O (1.45 g)
1.4 mM KH2PO4 (0.12 g)
Bring to 400 mL with dH2O, adjust pH to ~7.4, bring to 500 mL & filter sterilize
5x TBE electrophoresis buffer
0.445 M Tris base (54 g)
0.445 M Boric acid (27.5 g)
2 mL 0.5 M EDTA, pH 8.0
Bring upto 1 L with dH2O
5x TAE electrophoresis buffer
1 M Tris·acetate (24.2 g Tris base and 5.71 mL glacial acetic acid)
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50 mM EDTA (3.72 g Na2EDTA·2H2O)
Bring up to 1.0 L with dH2O, adjusting, if necessary, to pH ~8.5
TEN buffer
10 mM Tris-HCl (100 µL 1.0 M Tris-HCl, pH 8.0)
100 mM NaCl (1 mL 1 M NaCl)
1 mM EDTA (20 µL 0.5 M EDTA)
Bring up to 10 mL with dH2O
Bromophenol Blue
0.25% bromophenol blue (0.025 g)
20% Ficoll (2.0 g)
Bring up to 10 mL in dH2O
Bromophenol Blue/Xylenol Orange
0.25% xylenol orange
Add 0.0025 g xylenol orange to 1 mL bromophenol blue solution
Glycerol storage buffer for nuclei
0.05 M Tris-HCl, pH 8.3 (750 µL)
40% glycerol (6 mL)
0.005 M MgCl2 (0.00714 g)
0.0001 M EDTA (3 µL 0.5 M EDTA)
Bring up to 15 mL in dH2O
40% acrylamide (39 acrylamide:1 bisacrylamide)
19.5 g acrylamide
0.5 g bisacrylamide
Bring up to 50 mL with dH2O
degas under vacuum several minutes
lasts 30 days if stored in the dark and refrigerated
50 mL EMSA gel: 5% acrylamide
5 mL 5x TBE
6.25 mL 40% acrylamide (39 acryl:1 bisacryl)
38.75 mL dH2O
last minute:
400 µL 10% APS (ammonium persulfate, made fresh)
40 µL TEMED
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2% agarose gel
2 g agarose added to 100 mL 1x TAE buffer (make large quantity each time)
Heat and swirl to mix/pour
2X Transcription buffer (run-on transcription assay RNA synthesis):
0.2 M KCl (0.0149 g)
0.02 M Tris-HCl, pH 8.0 (20 µL 1 M Tris, pH 8.0)
0.005 M MgCl2 (100 µL 0.05 M MgCl2)
0.004 M DTT (40 µL 0.1 M DTT)
4 mM each ATP, GTP, and CTP (40 µL ea of 100 mM solutions)
0.2 M sucrose (0.0685 g)
20% glycerol (200 µL)
Bring up to 1 mL with dH2O
Dynal Solution A
0.1 M NaOH
0.05 M NaCl
Dynal Solution B
0.1 M NaCl
Dynal Binding buffer:
0.01 M Tris-HCl, pH 7.5 (10 µL 1 M Tris, pH 7.5)
0.001 M EDTA (2 µL 0.5 M EDTA)
2 M NaCl (0.1169 g)
Bring up to 1 mL with RNase-free H2O
SSC wash:
15% formamide (2.25 mL formamide in 12.75 mL 2x SSC)
2X standard saline citrate (SSC) (1.5 mL 20x SSC and 13.5 mL RNase-free H2O)
20X SSC (15 mL):
3 M NaCl (2.630 g)
0.3 M Na3citrate·2H2O (1.323 g)
Bring up to 15 mL with RNase-free H2O and adjust pH to 7.0
CaCl2
0.25 M CaCl2 (0.0368 g CaCl2·2H2O)
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Bring up to 1 mL with RNase-free H2O
Panomics Buffer A Mix
1 mL 1x Buffer A
10 µL 100 mM DTT
10 µL Protease Inhibitor Cocktail
40 µL 10% IGEPAL
Panomics Buffer B Mix
147 µL 1x Buffer B
1.5 µL Protease Inhibitor Cocktail
1.5 µL 100 mM DTT
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PURCHASED REAGENTS
Amersham Biosciences, Piscataway, NJ
Poly (dIdC)*Poly(dIdC) (10 A260 units, ~500 µL)--product # 27788001
ATCC, Manassas, VA
RPMI-1640 medium--item no. 30-2001
LNCaP FGC Prostate Cancer; Human--item no. CRL-1740
Beckman Coulter, Inc., Fullerton, CA
Spectrophotometer capillaries--part no. 514262
Bio-Synthesis Incorporated, Lewisville, TX
Estrogen response element and other primers--custom ordered
Cambrex Bio Science Walkersville, Inc., Walkersville, MD
0.025% Trypsin/0.265 mM EDTA solution (100 mL)--prod. code CC-5012
Corning Costar Corp., Cambridge, MA
25 cm2 Flask, tissue culture treated, polystyrene with phenolic style cap--item no.
430372
Dynal Biotech LLC, Brown Deer, WI
Dynabeads M-280 Streptavidin (10 mg/mL, 2 mL)--item no. 112.05
Fisher BioReagents, Fairlawn, NJ
Ribonuclease H (50 U, 2U/µL, 25 µL)--cat. no. BP3215-1
T4 Polynucleotide Kinase (100 U, 10U/µL, 10 µL)--cat. no. BP3212-1
HyClone, Logan, UT
Defined Fetal Bovine Serum (Lot # APA20504)--purchased from, catalog # SH30070
Invitrogen Life Technologies Corp., Carlsbad, CA
Random Primers (9 A260 U, 3 µg/µL)--cat. no. 48190-011
Ribonuclease H (30 U, 2 U/µL, 15 µL)--cat. no. 18201-014
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RNaseOUT Recombinant Ribonuclease Inhibitor (5000 U, 40 U/µL, 125 µL)--cat. no.
10777-019
Superscript II RNase H- Reverse Transcriptase (10000 U, 200 U/µL, 50 µL)--cat. no.
18064-014
TRIzol Reagent (100 mL)--cat. no. 15596-026
Panomics, Inc., Redwood City, CA
Nuclear Extraction Kit (10 reactions)--cat. no. AY2002
PerkinElmer Life Sciences, Inc. Boston, MA
Adenosine 5'-triphosphate (gamma-32P, 100 UCi, 3700 KBQ, 10 µL)--part no.
NEG002A100UC
Pierce, Rockford, IL
Slide-A-Lyzer Dialysis Cassette (10,000 MWCO, 0.1-0.5 ml capacity, 10 ea)--product #
0066415
Promega, Madison, WI
Magnesphere Magnetic separation stand (2-hole, 1.5 mL vial)--item no. Z5332
QIAGEN Sciences, Inc., Germantown, MD
QIAquick Nucleotide Removal Kit (50)--cat. no. 28304
QIAquick PCR Purification Kit (50)--cat. no. 28104
Roche Diagnostics Corp., Indianapolis, IN
Biotin-16-uridine-5'-triphosphate (250 nmol, 10 mM, 25 µL)--cat. no. 1 388 908
DNase I, RNase-free (10000 U, 10 U/µL, 1000 µL)--cat. no. 776 785
Ribonucleotide set (4x20 µMol, 200 µL, 100 mM lithium salt)--cat. no. 1 277 057
Santa Cruz Biotechnology, Santa Cruz, CA
Estrogen receptor beta antibody (N-19X)--item no. sc-6820 X
Sigma-Aldrich Corp., St. Louis, MO
(±)-α-tocopherol (5 g)--cat. no. T-3251
Bradford reagent (500 mL)--cat. no. B6916
Penicillin-Streptomycin Solution (100×) Stabilized (10,000 U/ml penicillin and 10 mg/ml
streptomycin, 100 mL)--cat. no. P4333
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RPMI-1640 Medium (with L-glutamine and without phenol red and sodium bicarbonate)-cat. no. R-8755
Sigmacote (100 mL)--cat. no. SL-2
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APPENDIX C
RAW DATA
Run-on transcription assay
* unusable data

Gene
18S

18S

18S

IGFBP10

IGFBP10

IGFBP10

Cdk2

Cdk2
Cdk2
Cathepsin D

Cathepsin D
hpS2

control
calculated
concentration
1.972
2.179
2.226
2.758
2.944
2.759
2.450
1.960
2.528
3.469
2.516
2.582
2.118
1.709
1.742
1.749
1.776
1.980
3.716
2.800
*
1.761
1.423
3.433
2.944
1.335
1.697
*
7.758
2.410
9.429

high
calculated
concentration
7.696
7.811
7.376
7.937
8.065
9.764
6.146
6.130
6.623
7.398
7.197
5.836
4.585
3.879
4.619
5.503
4.325
4.675
7.764
7.093
6.834
8.436
5.302
13.270
9.352
4.461
5.975
6.996
15.780
8.337
10.920
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fluorescence
crossing
noise
point
band
0.9
1.7

group
1

0.7

1.2

1

0.7

1.2

1

0.8

1.4

1

0.5

0.8

1

0.35

0.6

1

0.8

1.2

1

0.5

0.8

1

0.5

0.8

1

0.8

1.1

1

0.6

0.9

1

0.4

0.7

1

hpS2
hpS2

hpS2

18S

18S

IGFBP10

IGFBP10

Cdk2

Cdk2

Cdk2

Cathepsin D

Cathepsin D
Cathepsin D

20.350
0.915
*
1.573
4.742
1.607
5.456
*
*
4.527
4.648
4.731
5.840
6.049
6.150
3.478
2.977
2.611
6.292
4.937
6.305
12.290
4.277
6.980
17.580
20.500
13.190
10.600
7.999
13.250
8.385
7.223
*
10.090
3.259
2.156
4.492

14.930
13.870
7.582
9.191
5.726
*
8.410
2.801
5.569
5.579
6.046
5.382
7.278
7.293
7.184
5.640
4.454
5.881
9.911
7.766
8.436
7.337
9.620
7.295
14.300
21.540
17.550
6.028
13.950
4.519
7.710
7.389
9.441
7.657
*
5.035
3.947
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0.4

0.8

1

0..5

1.0

1

0.4

0.7

1

0.7

1.2

2

0.4

0.7

2

0.5

0.9

2

0.6

1.0

2

0.6

0.9

2

0.5

0.8

2

0.6
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2

0.4

0.7

2

0.55

0.75

2

0.3

0.45

2

Total RNA
* unusable data

Gene
18S

18S

18S

18S

IGFBP10

IGFBP10

IGFBP10

Cdk2

Cdk2

Cdk2

Cathepsin D

Cathepsin D

control
calculated
concentration
4.918
5.791
5.520
4.036
3.758
3.793
2.964
2.709
2.485
2.640
2.683
2.363
2.932
2.897
2.510
3.100
2.183
2.700
2.457
2.634
2.285
4.776
4.104
5.956
3.772
3.617
4.137
2.776
3.025
2.676
4.751
3.938
3.832
1.383
1.482

high
calculated
concentration
5.814
5.864
*
4.663
4.511
4.253
6.188
6.460
4.859
5.371
6.243
6.322
4.259
3.203
3.809
3.014
3.608
3.564
3.333
3.698
3.099
5.314
5.913
5.038
4.338
4.369
4.258
4.155
4.337
4.093
5.618
3.399
*
2.748
2.346
86

noise
band
0.9

fluorescence
crossing
point
1.2

group
1

0.8

1.0

1

0.8

1.2

2

0.6

1.0

2

0.6

0.8

1

1.3

1.5

1

1.25

1.5

1

0.8

1.0

1

1.2

1.5

1

1.0

1.2

1

1.0

1.2

1

1.0

1.2

1

Cathepsin D

hpS2

hpS2

hpS2

hpS2

*
3.459
3.414
3.293
3.733
3.549
3.668
2.678
1.782
1.840
2.562
2.795
1.852
2.361
1.929
3.119

2.126
9.349
7.016
9.553
4.516
4.273
5.921
5.732
5.286
5.745
5.248
6.125
4.485
6.260
5.927
6.083

87

1.2

1.5

2

0.75

1.1

1

0.6

1.0

2

0.7

1.1

2

0.5

0.9

2

STATISTICAL RAW DATA
Data set used was IGFBP10-ROTA group 1
Cumulative Cumulative
little Frequency
Percent
Frequency
Percent
-------------------------------------------------------------------------------Yes
6
100.00
6
100.00
Frequency Missing = 995
Cumulative Cumulative
big Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------Yes
994
100.00
994
100.00
Frequency Missing = 7
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------------------0.788128514
1001
100.00
1001
100.00
Data set used was IGFBP10-ROTA group 2
Cumulative Cumulative
little Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
957
100.00
957
100.00
Frequency Missing = 44
Cumulative Cumulative
big Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------Yes
43
100.00
43
100.00
Frequency Missing = 958
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
--------------------------------------------------------------------------------------1.3039873172
1001
100.00
1001
100.00
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Data set used was IGFBP10-total RNA group 1
Cumulative Cumulative
little Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
966
100.00
966
100.00
Frequency Missing = 35
Cumulative Cumulative
big Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------Yes
34
100.00
34
100.00
Frequency Missing = 967
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------------------1.2306934556
1001
100.00
1001
100.00
Data set used was Cathepsin D-ROTA group 1
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
288
100.00
288
100.00
Frequency Missing = 713
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------Yes
712
100.00
712
100.00
Frequency Missing = 289
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------------------0.8117872848
1001
100.00
1001
100.00
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Data set used was Cathepsin D-ROTA group 2
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
432
100.00
432
100.00
Frequency Missing = 569
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
----------------------------------------------------------------------------Yes
568
100.00
568
100.00
Frequency Missing = 433
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------------------0.95315059
1001
100.00
1001
100.00
Data set used was Cathepsin D-total RNA group 1
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
786
100.00
786
100.00
Frequency Missing = 215
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------Yes
210
100.00
210
100.00
Frequency Missing = 791
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------------------1.1396873797
1001
100.00
1001
100.00
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Data set used was Cathepsin D-total RNA group 2
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
486
100.00
486
100.00
Frequency Missing = 515
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
----------------------------------------------------------------------------Yes
514
100.00
514
100.00
Frequency Missing = 487
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------------------0.9743910102
1001
100.00
1001
100.00
Data set used was Cdk2-ROTA group 1
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
504
100.00
504
100.00
Frequency Missing = 497
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
----------------------------------------------------------------------------Yes
496
100.00
496
100.00
Frequency Missing = 505
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------------------0.997754091
1001
100.00
1001
100.00
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Data set used was Cdk2-ROTA group 2
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
222
100.00
222
100.00
Frequency Missing = 779
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------Yes
778
100.00
778
100.00
Frequency Missing = 223
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------------------0.789154991
1001
100.00
1001
100.00
Data set used was Cdk2-total RNA group 1
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
881
100.00
881
100.00
Frequency Missing = 120
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
----------------------------------------------------------------------------Yes
119
100.00
119
100.00
Frequency Missing = 882
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------------------1.1082037777
1001
100.00
1001
100.00
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Data set used was hpS2-total RNA group 1
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
749
100.00
749
100.00
Frequency Missing = 252
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
-----------------------------------------------------------------------------Yes
251
100.00
251
100.00
Frequency Missing = 750
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------------------1.0875649059
1001
100.00
1001
100.00
Data set used was hpS2-total RNA group 2
Cumulative Cumulative
little
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------Yes
968
100.00
968
100.00
Frequency Missing = 33
Cumulative Cumulative
big
Frequency
Percent
Frequency
Percent
----------------------------------------------------------------------------Yes
30
100.00
30
100.00
Frequency Missing = 971
Cumulative Cumulative
original
Frequency
Percent
Frequency
Percent
------------------------------------------------------------------------------------------1.2403714445
1001
100.00
1001
100.00
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COMPILED STATISTICAL DATA
Run-on
transcription

gene
IGFBP10
IGFBP10
Cdk2
Cdk2
Cathepsin D
Cathepsin D

calculated
mean
ratio
adjusted
to 18S
0.78813
1.30399
0.99775
0.78915
0.81179
0.95315

p-value
group
for <1 (replicates)
0.006
1 (9)
0.957
2 (6)
0.504
1 (7)
0.222
2 (9)
0.288
1 (5)
0.432
2 (7)

p-value weighted weighted
for >1
average probability
0.994
0.043 0.99447
0.385
0.496
0.778 0.88041
0.347
0.712
0.568 0.89427
0.372

Total RNA

gene

IGFBP10
Cdk2
Cathepsin D
Cathepsin D
hpS2
hpS2

calculated
p-value
p-value
mean
showing
showing
ratio
sig. for weighted weighted
sig. for
group
adjusted
>1
average probability
<1
(replicates)
to 18S

1.23069
1.10820
0.97439
1.13969
1.24039
1.08756

0.966
0.881
0.486
0.786
0.968
0.749

1 (9)
1 (9)
1 (6)
2 (3)
1 (3)
2 (9)
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0.034
0.119
0.514
0.210
0.030
0.251

1.23069
1.10820

0.034
0.119

1.02949

0.413

1.12577

0.196

FIG 4. LightCycler Results Example. Representative of typical output obtained from
the LightCycler. Calculated concentrations used above in the raw data section come
from the second to last column on the left portion of the image.
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